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Abstract approved:
Peroxisome proliferator-activated receptors (PPARs) are members of a
large group of ligand-regulated transcription factors that includes nuclear
receptors for steroid and thyroid hormones, retinoids and vitamin D3.
Synthetic fibrates and thiazolidinediones that bind to and activate PPARs are
used efficaciously in humans to remedy hypertriglyceridemia and non-insulin
dependent diabetes mellitus, respectively. The objective of the studies
described herein was to elucidate the molecular mechanisms of ligand-
dependent PPAR signaling.
Several PPAR ligands, including WY-14,643, were demonstrated to
directly induce PPARa conformational changes as evidenced by a differential
protease sensitivity assay. Conformational changes were induced in a dose-
dependent manner which paralleled that of ligand to induce transcriptional
activation. Direct interaction of ligands with, and the resulting conformational
alterations in, PPARa may facilitate interaction of the receptor with
transcriptional intermediary factors and thus may underlie the molecular basis
of ligand-dependent transcriptional activation mediated by PPARa.
Redacted for PrivacyThe yeast two hybrid screen was utilized  to  identify downstream 
components of the PPARa signaling pathway.  Using this technique, the 
coactivator proteins, p300 and steroid receptor coactivator-1 (SRC-1), were 
identified as PPARa-interacting proteins and WY-14,643 potentiated these 
interactions. p300 also enhanced the transcriptional activation properties of 
PPARa and, therefore, can be considered a bona fide coactivator for this 
nuclear receptor. Nuclear receptor corepressor (NCoR) was also isolated as 
a PPARa-interacting protein from a yeast two hybrid screen.  In contrast to the 
ligand enhanced PPARa-coactivator interactions, WY-14,643 inhibited NCoR 
interaction with PPARa. NCoR and the coactivators, p300 and SRC-1, were 
also demonstrated to require distinct receptor regions for efficient interaction 
with PPARa. 
Results described herein demonstrate that ligand  induces PPARa 
conformational changes, promotes PPARa-coactivator (p300 and SRC-1) 
interactions, and inhibits PPARa-NCoR interactions.  We hypothesize that 
such molecular events are  critical  for ligand-dependent  transcriptional 
activation by PPARa. These results contribute additional knowledge as to the 
molecular mechanisms of PPAR-dependent signaling and may act as a 
starting part for the improvement and/or development of therapeutic strategies 
aimed at manipulating this signaling pathway. © Copyright by Paul Dowell
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Chapter 1 
Introduction 
Peroxisome proliferator-activated receptors (PPARs) are members of a 
large group of ligand-regulated transcription factors that includes nuclear 
receptors for steroid and thyroid hormones, retinoids and vitamin D3. PPARs 
play a prominent role in the processes of peroxisome proliferation (Lee, et 
al., 1995c), lipid metabolism (Bardot, et al., 1993; Castelein, et al., 1994; 
lssemann, et al., 1992; Rodriguez, et al., 1994; Tugwood, et al., 1992), 
adipogenesis (Tontonoz, et  al.,  1994c) and inflammatory responses 
(Devchand, et al., 1996; Jiang, et al., 1998; Ricote, et al., 1998).  Synthetic 
fibrates (i.e., gemfibrozil) and thiazolidinediones (i.e., troglitazone) that bind 
to and activate PPARs (Devchand, et al., 1996; Lehmann, et al., 1995) are 
used efficaciously in humans to remedy hypertriglyceridemia (Witzum, 1995) 
and non-insulin dependent diabetes mellitus (NIDDM, Nolan, et al., 1994), 
respectively. The therapeutic benefits obtained from these agents are most 
likely due to activation of signaling pathways mediated by PPARs. 
The  molecular mechanisms  of  nuclear  receptor-mediated 
transcriptional modulation are not completely understood.  Evidence 
indicates that ligand bound receptors undergo conformational changes that 
concomitantly promote dissociation of receptor-associated corepressors and 
association of receptor-associated coactivators. Such molecular events, at 2 
least in part, are increasingly implicated in the process by which nuclear 
receptors modulate expression of target genes. 
1.1.  Nuclear receptor superfamily 
The nuclear receptor superfamily is composed of over 150 distinct 
transcription factors that function as regulators of embryonic development 
and influence a wide variety of biological processes (Mangelsdorf, et al., 
1995). Nuclear receptors are intracellular proteins that bind cognate ligands 
with high affinity and specificity, recognize sequence specific response 
elements and modulate expression of target genes.  The superfamily is 
separated into three general categories composed of steroid hormone (ie; 
glucocorticoid and estrogen receptors), retinoid/thyroid hormone (ie; retinoic 
acid and retinoid X receptors) and orphan (ie; COUP-TF) receptors (Fig. 1.1). 
The proteins within the steroid and retinoid/thyroid hormone groups respond 
to at least one distinct ligand while no ligands have been identified for 
receptors within the orphan group. 
All  receptors within the superfamily exhibit an evolutionarily 
conserved, characteristic pattern of protein domains that have been 
classified as A/B, C, D and E (Fig. 1.2, Evans, 1988; Green and Chambon, 
1988).  The variable amino-terminal A/B region contains a ligand­
independent transactivation function also known as AF-1.  The C region 
contains a highly conserved core of 66-68 amino acids that functions as the 
DNA binding domain.  This region contains two zinc-finger motifs, each 
containing four Cys residues, that tetrahedrally coordinate one zinc ion (Fig. 
1.2). The D region, also termed the hinge domain, is a variable segment that 
contains a nuclear localization signal and, for some receptors, functions as a 3 
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Fig. 1.2. Domain structure of nuclear receptors and comparison of
PPAR subtypes. Demarcations for A/B, C, D and E domains of PPAR 
subtypes are shown as boxes and amino acid number is indicated above. 
Schematic representation of the highly conserved zinc fingers contained 
within the C domain is illustrated at top. Boxed numbers represent percent of 
amino acid conservation for each domain of the p/s and y subtypes as 
compared to those within PPARa. The additional 30 amino acids of the 
PPARy2 isoform are indicated by brackets. Ligand-independent and 
-dependent transactivation functions are AF-1 and AF-2, respectively. Ligand 
binding domain = LBD. 5 
protein interaction surface. The E region is a multifunctional domain involved 
in  ligand binding, ligand-dependent transactivation (AF-2),  receptor 
oligomerization (homo/heterodimerization) and accessory protein interaction. 
1.2.  Peroxisome proliferator-activated receptors 
In 1990, Issemann and Green (Issemann and Green, 1990) identified 
PPARa as a novel mouse nuclear receptor that was activated by a group of 
structurally diverse compounds known as peroxisome proliferators (PPs). 
Several therapeutically useful hypolipidemic agents (i.e., gemfibrozil and 
clofibric acid), industrial solvents, plasticizers and herbicides are contained 
within this group of compounds. PPs, when administered to rodents, elicit 
proliferation of hepatic peroxisomes, induction of peroxisomal fatty acid-
oxidizing enzyme activities and an increase in hepatocarcinogenesis (Lake, 
1995). Mice null for expression of PPARa are resistant to the hepatomegaly 
and peroxisome proliferating affects of PPs indicating that the a subtype is 
the principal mediator of this biological response (Lee, et al., 1995c). 
PPARa is expressed predominantly in heart, liver and kidney tissues 
of the mouse and appears to function primarily as a regulator of lipid 
metabolism (Issemann and Green, 1990).  PPAR response elements 
(PPREs) have been identified within the regulatory regions of several genes 
involved in fatty acid metabolism including acyl-CoA oxidase (Tugwood, et 
al., 1992; Varanasi, et al., 1996), bifunctional enzyme (Bardot, et al., 1993; 
Zhang, et al., 1992) and malic enzyme (Castelein, et al., 1994). The clear 
role of PPARa in regulating lipid metabolism, particularly the peroxisomal p-
oxidation of fatty acids, offers a molecular explanation for the therapeutic 
benefits obtained when using PPARa activators, such as gemfibrozil and 
clofibric acid, to treat hyperlipidemias. The safety of these drugs, however, 6 
has  been  questioned  because  of  their  ability  to  promote 
hepatocarcinogenesis in rodents despite the lack of evidence for a similar 
phenomenon in humans (Rao and Reddy, 1996).  The precise molecular 
mechanisms  of  peroxisome  proliferation  and  associated 
hepatocarcinogenesis in rodents, and lack thereof in humans, remain 
elusive. 
Recent studies indicate that the endogenous ligand for PPARa is the 
arachidonic acid metabolite and inflammatory agent, leukotriene B4 (LTB4, 
Devchand, et al., 1996, Fig. 1.1).  Devchand et al (1996) hypothesize that 
PPARa may regulate the duration of the inflammatory response through a 
negative feedback mechanism.  Because PPARa regulates the oxidative 
catabolism of fatty acids, such as LTB4, increased activation of PPARa leads 
to increased catabolism of LTB4 thereby abolishing the inflammatory 
mediator. 
Since the discovery of the first PPAR, the a subtype, two additional 
related subtypes, 6 (also known as [3) and 7 (Fig. 1.2), have been identified in 
mouse (Kliewer, et al., 1994), human (Greene, et al., 1995; Schmidt, et al., 
1992; Sher, et al., 1993) and Xenopus (Dreyer, et al., 1992). The 5 subtype 
of PPAR is expressed ubiquitously in mouse tissues (Kliewer, et al., 1994) 
and remains the least well characterized of all the subtypes. The synthetic 
fibrate, benzafibrate, is the only compound that has been shown to activate 
PPAR but this compound also activates the a and y subtypes indicating poor 
specificity (Krey, et al., 1997). Kliewer et al (1994) demonstrated that PPARS 
can functionally antagonize other members of the PPAR family but no clear 
physiological roles have been ascribed to this subtype. 
Two isoforms of the third PPAR subtype, y, have been identified in 
mouse and human (Fajas, et al., 1997; Zhu, et al., 1995).  Differential 7 
promoter usage and alternative splicing give rise to distinct mRNAs resulting 
in 71 and -y2 protein products that differ only by an additional thirty amino 
acids in the amino-terminus of PPAR72 (Fig. 1.2).  Distinct physiological roles 
for yi and y2 have not been identified.  As discovered for PPARy, an 
arachidonic acid derivative, 15-deoxyAl2-14prostaglandin J2 (15d-PGJ2, Fig. 
1.1), appears to be at least one of the natural ligands for PPARy (Forman, et 
al., 1995; Kliewer, et al., 1995). Synthetic thiazolidinediones (TZDs) also act 
as PPARy ligands (Lehmann, et  al.,  1995) and are currently used 
efficaciously to improve insulin sensitivity in skeletal muscle and adipose 
tissue of NIDDM patients (Nolan, et al., 1994). The biological mechanisms of 
TZD-mediated improvements in insulin sensitivity are not known but are 
thought to occur through PPARy- dependent signaling pathways. 
PPARy was originally identified as an adipocyte-specific gene 
regulatory factor and accordingly is expressed at high levels in adipose 
tissue (Chawla, et al., 1994; Tontonoz, et al., 1994a; Tontonoz, et al., 1994b). 
Subsequent studies demonstrated that ectopic expression of PPARy in a 
non-adipogenic fibroblast cell line was sufficient to confer adipogenicity 
indicating that this PPAR subtype functions as a dominant adipogenic factor 
(Tontonoz, et al., 1994c). Recent evidence indicates that certain nonsteroidal 
anti-inflammatory drugs may act through PPARy to antagonize production of 
macrophage-derived inflammatory cytokines (Jiang, et al., 1998; Ricote, et 
al., 1998).  In addition, PPARy has been demonstrated to promote the 
conversion of macrophages into artherosclerotic lesion-forming foam cells 
(Nagy, et al., 1998; Tontonoz, et al., 1998). These findings may aid in the 
development of therapeutic strategies that target PPARy for the treatment of 
chronic inflammatory diseases and artherosclerosis. When considering the 
available evidence surrounding the physiological roles of PPAR subtypes, 8 
common functions in regulating lipid homeostasis and inflammation appear 
to be most prominent.  It will be of interest to determine any additional 
biological roles that PPAR subtypes may serve. 
PPARs modulate expression of target genes by binding to response 
elements comprised of a degenerate direct repeat of the hexameric 
nucleotide sequence, TGACCT, separated by one base pair (DR1). All PPAR 
subtypes bind to cognate response elements only in the context of a 
PPAR/retinoid X receptor (RXR) heterodimeric complex (Gearing, et al., 1993; 
lssemann, et al., 1993; Keller, et al., 1993; Kliewer, et al., 1992; Varanasi, et 
al., 1996). PPAR/RXR heterodimeric complexes appear to be responsive to 
both PPAR activators and 9-cis retinoic acid (9-cis-RA), the endogenous 
ligand for RXR (Gearing, et al., 1993; Keller, et al., 1993; Kliewer, et al., 
1992). 
1.3.  Nuclear receptor-mediated transcriptional activation 
1.3.1.  Coactivators 
The precise molecular mechanisms underlying ligand activation of 
nuclear receptors and subsequent transcriptional modulation remain to be 
completely understood.  Initial evidence implicating receptor associated 
coactivator proteins came from observations that progesterone receptor (PR) 
could antagonize the activation potential of estrogen receptor (ER) and vice 
versa (Meyer, et al., 1989).  These seminal observations suggested that 
nuclear receptors utilize common, titratable cellular factors that are required 
for transcriptional activation.  The first biochemical evidence for nuclear 
receptor-associated coactivators was reported by Halachmi et al (1994) and 9 
Cavailles et at (1994).  Both groups identified cellular proteins termed 
estrogen receptor-associated proteins (ERAPs, Halachmi, et al., 1994) and 
receptor-interacting proteins (RIPs, Cavailles, et al., 1994) that associated 
with ligand-bound, but not unliganded, ER. 
The first molecularly cloned coactivator, steroid receptor coactivator 1 
(SRC-1), was identified as a ligand-bound PR-interacting protein that 
enhanced the ligand-dependent transcriptional activation properties of PR 
and several other nuclear receptors (Onate, et al., 1995).  Antagonism 
between PR and ER transcriptional activation properties was reversed by 
overexpression of SRC-1 suggesting that this coactivator was responsible for 
the similar, previous observations (Meyer, et  al.,  1989) and/or could 
functionally substitute for a second unidentified coactivator (Onate, et al., 
1995). The SRC-1 gene encodes at least one of the previously identified 
ERAPs and is now known to be one member of an increasingly large group 
of related coactivators that includes TIF2/GRIP1 (Hong, et al., 1996; Voegel, 
et al., 1996), RAC3 (Li, et al., 1997), AIB1 (Anzick, et al., 1997), ACTR (Chen, 
et al., 1997) and p/CIP (Torchia, et al., 1997, Fig. 1.3A). A second group of 
nuclear receptor coactivators that neither exhibits homology to each other 
nor to other groups of coactivators includes RIP140 (Cavailles, et al., 1995), 
ARA70 (Yeh and Chang, 1996), SUG-1/TRIP1 (Lee, et al., 1995b; Vom Baur, 
et al., 1996), TIF1 (LeDouarin, et al., 1995), PBP/TRIP2 (Lee, et al., 1995a; 
Zhu, et al., 1997) and PGC-1 (Puigserver, et al., 1998, Fig. 1.3A). 
p300 and CREB binding protein (CBP) constitute a third group of 
nuclear receptor coactivators that were originally identified as adenovirus 
E1A- (Eckner, et al., 1994) and CREB-associated molecules (Chrivia, et al., 
1993), respectively. p300 and CBP are distinct but highly related proteins of 
-300 kDa and appear to be functionally homologous (Arany, et al., 1994; 10 
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Fig. 1.3. Nuclear receptor coactivator groups. A The three general 
groups of coactivators and members of each group are listed. SRC-1=steroid 
receptor coactivator  1,  TIF2=transcriptional  intermediary factor  2, 
GRIP1=glucocorticoid receptor interacting protein  1, p/CIP=p300/CBP 
interacting protein, RAC3=receptor associated coactivator 3, AlB1=amplified 
in breast cancer 1, ACTR=activating component for thyroid hormone and 
retinoid receptors, SUG-1= murine homolog of the yeast protein, ySUG-1, 
TRIP1=thyroid hormone receptor interacting protein 1, TIF1=transcriptional 
intermediary factor 1, RIP140=receptor interacting protein of 140 kDa, 
ARA70=androgen receptor, PBP=PPAR binding protein, TRIP2=thyroid 
hormone receptor interacting protein 2, PGC-1=PPARy coactivator 1. See 
text for references. 8, Schematic representation of SRC-1 and p300/CBP. 
Interaction domains are indicated by lines with the interacting proteins listed 
below. Regions that mediate histone acetyltransferase activity are indicated 
by black boxes and the bromodomain of p300/CBP is shown as a shaded 
box. 11 
Lundblad, et al.,  1995).  p300 and CBP have been termed integrator 
proteins(Kamei, et al., 1996) because multiple signaling pathways converge 
at and require these proteins for activity (Fig. 1.38).  In contrast, proteins 
within the SRC-1 family appear to function exclusively as nuclear receptor 
coactivators. 
The integrator proteins were originally implicated in nuclear receptor 
signaling by the observation that several receptors potently antagonize 
transcriptional activation by the unrelated factor, activator protein-1 (AP-1, 
Beato, et al., 1995).  Kamei et al (Kamei, et al., 1996) reasoned that the 
integrator proteins, which were known to act as coactivators for AP-1 (Arias, 
et al., 1994), might also function as coactivators for nuclear receptors thus 
providing a molecular explanation  for the observed antagonism. 
Subsequent studies demonstrated a ligand-dependent interaction between 
p300/CBP and several nuclear receptors that resulted in enhanced nuclear 
receptor transcriptional activation properties (Chakravarti, et al.,  1996; 
Kamei, et al., 1996).  In addition, overexpression of p300/CBP was sufficient 
to relieve repression of AP-1 activity by ligand-activated nuclear receptors 
indicating that AP-1 and nuclear receptors compete for limiting amounts of 
the integrator proteins (Kamei, et al., 1996). p300/CBP was also shown to 
interact directly with the previously identified nuclear receptor coactivator, 
SRC-1 (Kamei, et al., 1996).  When considered together, these findings 
indicated the existence of a liganded nuclear receptorp300/CBPSRC-1 
complex that mediates ligand-dependent transcriptional activation. 
1.3.2.  Histone acetyltransferase activities 
Soon after the discovery of several nuclear receptor coactivators, 
Yang et al (Yang, et al., 1996) identified a p300/CBP-associated factor 12 
(P/CAF) that exhibited histone acetyltransferase (HAT) activity.  Multiple 
groups subsequently demonstrated that p300/CBP, SRC-1 and several other 
coactivators also possessed intrinsic HAT activity (Fig. 1.3B, Bannister and 
Kouzarides, 1996; Chen, et al., 1997; Mizzen, et al., 1996; Ogryzko, et al., 
1996; Spencer, et al.,  1997).  These findings, coupled with previous 
demonstrations that hyperacetylated histones are associated with actively 
transcribed chromatin (Hebbes, et al., 1988), provided a molecular link 
between ligand-activated nuclear receptors and transcriptional activation of 
target genes. 
The mechanisms whereby histone acetylation leads to activation of 
gene expression is not thoroughly understood.  Struhl (Struhl, 1998) 
proposes a model in which acetylation of lysine residues on histones 
neutralizes the positive charge thereby decreasing the affinity of histones for 
negatively charged DNA (Hong, et al., 1993). Nucleosomal conformation is 
consequently altered which allows access of transcriptional regulatory 
proteins (ie; the basal transcription machinery) to chromatin templates (Lee, 
et al., 1993; Vettese-Dadey, et al., 1996). 
Systematic examination of the HAT activities associated with each 
component of the nuclear receptor-coactivator complex indicate that the HAT 
activities of all identified coactivators, with the exception of P/CAF, are 
dispensable for ligand-dependent nuclear receptor mediated transcriptional 
activation (Korzus, et al., 1998). Thus, it appears that most of the nuclear 
receptor-associated coactivators primarily function as a molecular scaffolding 
for the arrangement of the transcriptional activation complex while P/CAF, in 
addition to contributing to the scaffolding, provides the necessary HAT 
activity. 13 
1.4.  Nuclear receptor-mediated transcriptional repression 
1.4.1.  Corepressors 
In addition to activating expression of target genes upon binding 
ligand, several nuclear receptors actively repress genes to sub-basal levels 
in the absence of ligand (Damm, et al., 1989; Graupner, et al., 1989). 
Receptor regions within the D and E domains were initially implicated in the 
repression functions of TR and RAR by their ability to function as autonomous 
transcriptional repressors when fused to heterologous DNA binding domains 
(Baniahmad, et al., 1993; Baniahmad, et al., 1992; Holloway, et al., 1990). 
Ligand was hypothesized to induce a nuclear receptor conformational 
change that resulted in dissociation of a soluble corepressor protein and 
relief of transcriptional repression (Baniahmad, et al., 1995).  Evidence in 
support of this hypothesis was put forth when the first corepressor proteins, 
nuclear receptor corepressor (NCoR) and silencing mediator for retinoid and 
thyroid-hormone receptors (SMRT), were cloned and demonstrated to 
facilitate nuclear receptor repression and be released from receptors upon 
binding ligand (Chen and Evans, 1995; Horlein, et al., 1995). NCoR and 
SMRT exhibit extensive homology and both contain nuclear receptor 
interaction domains within the carboxyl-terminal regions (Fig.  1.4). 
Additionally, NCoR and SMRT domains located within the amino-terminal 
function as autonomous transcriptional  repressors when fused to 
heterologous DNA binding domains (Chen and Evans, 1995; Horlein, et al., 
1995). SMRT REPRESSION
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Fig. 1.4. Nuclear receptor corepressors. Schematic representation of SMRT and NCoR. Interaction 
domains are indicated by lines with the interacting proteins listed below. Nuclear receptor interaction domains 
are shown as black boxes. SMRT and NCoR domains that mediate transcriptional repression are shown. 15 
1.4.2.  Histone deacetyltransferase activities 
Heinzel  et  al  (1997) and Nagy et  al  (1997) subsequently 
demonstrated that NCoR and SMRT, individually, are components of a larger 
complex containing mSin3A and histone deacetylase 1 (HDAC1). mSin3A 
and HDAC1 are mammalian homologs of the yeast HO gene repressor, 
Sin 3p, and associated yeast histone deacetylase, Rpd3p, respectively (Ayer, 
et al., 1995; Schreiber-Agus, et al., 1995; Taunton, et al., 1996). Unliganded 
receptor interactions with NCoR/SMRT and associated mSin3A and HDAC1 
were correlated with the ability of nuclear receptors to actively repress 
transcription (Heinzel, et al., 1997; Nagy, et al., 1997).  While the amino-
terminal repression domains of NCoR and SMRT were shown to interact 
directly with mSin3A, no direct interactions were detected between either 
NCoR and HDAC1, SMRT and HDAC1 or mSin3A and HDAC1 indicating 
that additional factors may be present within this complex (Heinzel, et al., 
1997; Nagy, et al., 1997).  Nonetheless, these results, when considered 
together with previous observations that hypoacetylated histones are 
associated with non-transcribed chromatin (Hebbes, et al., 1988), provided a 
molecular link between unliganded nuclear receptors and transcriptional 
repression of target genes. 
1.5.  Current model of nuclear receptor-mediated transcriptional
modulation 
Over the past decade, a large body of experimental evidence has 
begun to illuminate the precise mechanisms of nuclear receptor-mediated 
transcriptional regulation.  The model represented in Fig. 1.5 illustrates 
hypothetical PPARRXRPPRE complexes in dynamic equilibrium between 
repressed and activated states.  In this model, ligand binding by the receptor 16 
PPAR TARGET GENE 
Repressed 
CD 
Activated 
Fig.  1.5. Model  for  nuclear receptor-mediated transcriptional
regulation. Hypothetical PPARRXRPPRE complexes in dynamic 
equilibrium  between  activated  and  repressed  states.  HDAC 
deacetyltransferase and p/CAF acetyltransferase activities are represented 
by curved arrows terminating at histone substrates. Ligand is represented by 
shaded ovals. 17 
promotes formation of the activated state while ligand dissociation from the 
receptor promotes formation of the represed state.  Receptor species can 
exist at any point in the spectrum from fully repressed to fully activated 
allowing for a wide variability in signaling capabilities.  In addition, the 
cellular concentrations of receptors, corepressors and coactivators influence 
the equilibrium and may vary considerably depending upon the cell type or 
cellular status.  Such a model will become increasingly complex when 
biological parameters such as protein-protein affinities, allosteric regulation 
by DNA response elements and influences of heterodimeric partners are 
also considered. 
1.6.  Research objectives 
The goal of the studies described herein was to contribute toward a 
more thorough understanding of PPAR-ligand interactions and how such 
interactions ultimately lead to transcriptional regulation.  A variety of 
molecular biological techniques were applied to  in vitro and ex vivo 
experimental settings throughout the research conducted. The specific aims 
are detailed in the following paragraphs. 
Chapter 2 describes studies that examine the ability of several PPAR 
ligands to bind to and induce receptor conformational changes.  Induced 
conformational changes likely underlie the molecular basis of ligand­
dependent transcriptional activation and therefore are  of  interest. 
Experiments were conducted with PPAR truncation mutants to identify amino 
acids that are required for ligand binding, ligand-induced conformational 
changes and  heterodimerization  with  RXR.  The  influence  of 
heterodimerization with RXR on the ability of PPAR to bind ligand and 
undergo conformational changes was also examined. 18 
Chapters 3 and 4 describe the findings from several PPAR protein-
protein interaction screens.  The yeast two hybrid system was utilized to 
identify downstream components of the PPAR signaling pathway.  Proteins 
that interact with both liganded and unliganded PPAR were isolated and 
comparatively examined for interaction with the retinoid receptors, RAR and 
RXR.  Differential interactions between members of the nuclear receptor 
superfamily and common downstream signaling components may play a 
critical role in mediating cooperative or antagonistic signal transduction 
mediated by these receptors. 
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2.1.  Abstract 
Structurally diverse peroxisome proliferators and related compounds 
that have been demonstrated to induce the ligand-dependent transcriptional 
activation function of mouse peroxisome proliferator-activated receptor a 
(mPPARa) in transfection experiments were tested for the ability to induce 
conformational changes within mPPARa in vitro.  WY-14,643, 5,8,11,14­
eicosatetraynoic acid (ETYA), LY-171883, and clofibric acid all directly 
induced mPPARa conformational changes as evidenced by a differential 
protease sensitivity  assay.  Carboxyl-terminal terminal truncation 
mutagenesis of mPPARa differentially affected the ability of these ligands to 
induce mPPARa conformational changes suggesting that PPAR ligands may 
make distinct contacts with the receptor.  Direct interaction of peroxisome 
proliferators and related compounds with, and the resulting alteration(s) in 
mPPARa conformational states may facilitate interaction of the receptor with 
transcriptional intermediary factors and/or the general transcription 
machinery and, thus, may underlie the molecular basis of ligand-dependent 
transcriptional activation mediated by mPPARa. 
2.2.  Introduction 
Peroxisome proliferator-activated receptors (PPARs) are members of a 
large family of ligand-inducible transcription factors that includes receptors 
for retinoids, vitamin D, and thyroid and steroid hormones (Evans, 1988; 
Green and Chambon, 1988; Leid, et al., 1992a; Mangelsdorf, et al., 1995; 
Tsai and O'Malley, 1994). The mammalian PPAR family is composed of at 
least three genetically- and pharmacologically-distinct subtypes: PPARa, -y, 
and -5 (reviewed in Green, 1995). Murine PPAR a (mPPARa) was originally 29 
isolated from a mouse liver cDNA library by Isseman and Green who 
demonstrated that the receptor was activated in transfection experiments by 
a group of compounds known to induce peroxisome proliferation in rodents 
(Issemann and Green, 1990). A number of structurally diverse compounds 
have subsequently been demonstrated to activate PPARa in transient 
transfection experiments.  Particularly noteworthy among these compounds 
are: 1) lipids such as arachidonic acid (Dreyer, et al., 1993; Gott licher, et al., 
1992; Issemann, et al., 1993a; Keller, et al., 1993) and its synthetic analog 
5,8,11,14-eicosatetraynoic acid (ETYA, Dreyer, et al., 1993; Hsu, et al., 1995; 
Keller, et al., 1993; Mukherjee, et al., 1994), 8-[S]-hydroxyeicosatetraenoic 
acid (8[S]-HETE; Yu, et al., 1995), a lipoxygenase metabolite of arachidonic 
acid, and linoleic acid (Dreyer, et al., 1993; Gott licher, et al., 1992; Issemann, 
et al., 1993a; Keller, et al., 1993; Rodriguez, et al., 1994; Yu, et al., 1995); 2) 
fibric acid anti-hyperlipidemic drugs (WY-14,643, clofibric acid, gemfibrozil, 
ciprofibric acid; Castelein, et al., 1994; Issemann, et al., 1993a; Varanasi, et 
al., 1996) that represent a class of therapeutic agents useful in the treatment 
of hypertriglyceridemia (Witzum, 1995); and 3) a leukotriene D4 antagonist, 
LY-171883 (Kliewer, et al., 1994). Many of these compounds, together with 
phthalate ester plasticizers (di(-2-ethylhexyl)-phthalate) and herbicides 
(2,4,5-trichlorophenoxyacetic acid) are known collectively as peroxisome 
proliferators (reviewed in Lake, 1995).  While chemically distinct, most of 
these compounds have been demonstrated to induce proliferation of 
peroxisomes leading to hepatic hyperplasia and hepatocarcinogenesis in 
many species (Lake, 1995).  Peroxisome proliferator-induced alteration of 
hepatocyte phenotype is believed to result from activation of PPARa and 
subsequent modulation of gene expression downstream of this nuclear 
receptor (reviewed in Green, 1995 and Lake, 1995; see below). The central 30 
role of PPARa in xenobiotic-induced peroxisomal proliferation was recently 
demonstrated by the absence of hepatomegaly and peroxisome proliferation 
in mice null for expression of this gene (Lee, et al., 1995). 
PPARs modulate expression of target genes by binding to response 
elements comprised of a degenerate direct repeat of the hexameric 
nucleotide sequence, TGACCT, separated by one base pair (DR1). PPAR 
has been shown to bind cognate response elements with high affinity only in 
the context of a heterodimeric complex with the retinoid X receptor (RXR, 
Gearing, et al., 1993; Issemann, et al., 1993b; Keller, et al., 1993; Kliewer, et 
al., 1992; Varanasi, et al., 1996).  PPAR/RXR heterodimeric complexes 
appear to be responsive to both PPAR activators and 9-cis retinoic acid (9­
cis-RA), the endogenous ligand for RXR (Gearing, et al., 1993; Issemann, et 
al., 1993b; Keller, et al., 1993; Kliewer, et al., 1992; Varanasi, et al., 1996). 
PPAR response elements (PPREs) have been identified in the 5' 
regions of several mammalian genes coding for proteins involved in lipid 
metabolism such as acyl-CoA oxidase (Tugwood, et al., 1992; Varanasi, et 
al., 1996), bifunctional enzyme (Bardot, et al., 1993; Zhang, et al., 1992a), 
malic enzyme (Castelein, et al.,  1994), liver fatty acid binding protein 
(Issemann,  et  al.,  1992), 3-hydroxy-3-methylglutaryl-CoA synthase 
(Rodriguez, et al., 1994), and cytochrome P450 fatty acid co-hydroxylase 
(Muerhoff, et al., 1992). Such findings indicate a prominent regulatory role 
for the PPAR receptor family in  lipid metabolism and homeostasis.  In 
addition, overexpression of PPARa and -y in cultured fibroblasts and 
subsequent exposure to PPAR ligands has been shown to confer 
adipogenicity (Brun, et al., 1996; Tontonoz, et al., 1994) further illustrating the 
central regulatory role of PPAR family members in lipid homeostasis. 31 
In contrast to many other receptors in the retinoid/thyroid hormone 
receptor superfamily, functional domains of PPARs and critical amino acid 
residues within such putative domains have not been extensively 
characterized. Two previous studies with PPARa have identified: 1) a 
Glu282--Gly point mutation in mPPARa that ameliorates transcriptional 
responses to WY-14,643 and ETYA (Hsu, et al., 1995), and 2) a LeU433>Arg 
point  mutation  in  human PPARa (hP PA R a)  which  abolishes 
heterodimerization with RXR (Juge-Aubry, et al., 1995). The present studies 
were undertaken to identify mPPARa carboxyl-terminal receptor regions that 
are important for both ligand responsiveness and heterodimerization with 
mRXRa and to determine if structurally-diverse PPAR ligands induce similar 
conformational changes within mPPARa. To our knowledge, these studies 
provide the first direct biochemical evidence demonstrating that peroxisome 
proliferators induce conformational changes within mPPARa. Ligand­
induced stabilization of particular mPPARa conformational states likely 
underlies the molecular basis for the ability of these compounds to activate 
the receptor and to modulate expression of mPPARa target genes including 
those implicated in peroxisome proliferation. 
2.3.  Materials and Methods 
2.3.1.  Plasmids and receptor contructs 
Full-length mPPARa (lssemann and Green, 1990) was kindly 
provided by Drs. S. Green and J. Tugwood (Macclesfield, UK) and was used 
as a template for the polymerase chain reaction during construction of all 
PPAR mutants described herein. Full-length mouse RXRa (mRXRa, Leid, et 32 
al., 1992b) and pGEX-cs (Parks, et al., 1994) were kind gifts from Drs. Ph. 
Kastner and P. Chambon (Strasbourg) and Dr. W. Dougherty (Oregon State 
University), respectively. 
A mPPARa amino terminal truncation mutant was constructed by PCR 
using a 5' primer (ML023) that introduced an EcoRl site, favorable Kozak 
sequence, and an initiator methionine fused to Asp91 of mPPARa and a 3' 
primer that introduced a BamHl site 3' of the mPPARa natural stop codon. 
The resulting fragment was appropriately digested and subcloned into the 
eukaryotic expression vector, pTL1 (Leid, et al., 1992b), yielding PPARAAB. 
PPARAAB is transcribed/translated in vitro at least 10-fold more efficiently 
than full-length receptor and exhibits DNA binding and heterodimerization 
activities that are indistiguishable from full length receptor (data not shown). 
The carboxy terminal  truncation  mutants, PPARAAB/A448 and 
PPARAAB/A425 (Fig. 2.1A), were prepared by PCR using ML023 as the 5' 
primer and a 3' primer that introduced stop codons at positions 448 and 425, 
respectively, preceding a BamHl site.  Both of the resulting fragments were 
appropriately digested and subcloned into pTL1 as described above. 
PPAR AAB,  PPARAAB/A 448,  and  PPARAAB/A 425  were 
transcribed/translated in vitro with equal efficiencies (data not shown). 
GST-mRXRa was prepared by PCR amplification of full length mRXRa 
using a 5' primer that introduced a Hincll site immediately upstream of the 
natural initiator methionine and a 3' primer that introduced an EcoRl site 3' of 
the natural stop codon of mRXRa. The resulting fragment was appropriately 
digested and subcloned into a Ehel/EcoRI-digested GST fusion vector 
(pGEX-cs). 33 
2.3.2.  In vitro transcription/translation 
Proteins were prepared by in vitro transcription/translation using rabbit 
reticulocyte lysate as previously described (Leid, et al., 1992a; Leid, et al., 
1992b).  Translation reactions were carried out in the presence of 
[35S]methionine for production of radioactively labeled proteins used in 
DPSAs and GST-pull down experiments, whereas receptor proteins used in 
electrophoretic mobility shift assays were translated in the presence of 
unlabeled methionine.  Unprogrammed lysates were generated identically 
using equal amounts of linearized pTL1  in place of receptor-coding 
templates. 
2.3.3.	  Electrophoretic mobility shift assays (EMSA)
 
Two probes were used in these studies:
 
DR1:	  5'- cgagTGACCTcTGACCCctaccctcga -3' 
ACO-PPRE:  5'- cttcgcgaacgTGACCTtTGTCCTccccttttgctcgatc -3' 
One strand of each probe is shown for clarity and the directly repeated motifs 
are indicated in uppercase letters and by underlining. Both DR1 (Leid, 1994; 
Mader, et al., 1993) and ACO-PPRE (Tugwood, et al., 1992) probes have 
been described previously. 
Receptor proteins (10 and 20 fmols of PPARAAB and mRXRoc, 
respectively) were preincubated on ice for 15 minutes prior to addition of a 
mix containing -50,000 cpm of Klenow end-filled DR1 or ACO-PPRE probes. 
Components of the probe mix were (in mm): HEPES-NaOH pH 7.5, 10; 
EDTA, 1; DTT, 1; and NaCI, 150. The mix was supplemented with 10% 
glycerol, 1  ig/1_11 bovine serum albumin and poly [dl  dC] (2 lig / tube). The 34 
amount of lysate in each binding reaction was held constant by addition of 
unprogrammed reticulocyte lysate.  Samples were loaded on a 5% 
polyacrylamide gel, electrophoresed, and gels were dried and subjected to 
autoradiography as previously described (Leid, 1994; Leid, et al., 1992b). 
2.3.4.  Bacterial expression and purification of GST and GST­
mRXRa fusion proteins 
GST-mRXRa expression in the DH5aF' strain of E. coli was induced 
by addition of isopopyl 13-D-thiogalactopyranoside  (IPTG; 1mm final 
concentration) to the growth media and cultured for an additional 2 hours. 
Bacterial extracts were prepared using standard methods. The fusion protein 
was purified on a glutathione sepharose 4B column as per the 
manufacturer's (Pharmacia) recommendations. 
2.3.5.  GST pull-down experiments 
Glutathione sepharose 4B (Pharmacia) was washed extensively in 
phosphate buffered saline (PBS) and resuspended in a volume of PBS 
sufficient to generate a 50% slurry.  This slurry (1 ml) was mixed with 2 
volumes of PBS (2 ml) containing either no protein, purified GST, or purified 
GST-mRXRa (proteins were at a concentration of 1 mg/ml) and incubated 
with rotation at 4°C overnight.  The resin slurry was gently centrifuged, 
washed 5 times in 2 volumes of PBS (2 ml) to remove all unbound protein, 
and finally resuspended in 1 volume of binding buffer (same as EMSA buffer 
but without poly [dI  dC]). GST pull-down experiments were conducted using 
20 41(100 fmol) of in vitro translated [35S]PPARAAB, [35S]PPARAAB/A448, or 
[35S]PPARAAB/A425 and 40111 of GST bound, GST-mRXRa bound, or 
unbound glutathione sepharose slurries.  After an overnight incubation at 35 
4°C with continuous rotation, samples were gently centrifuged and washed 
10 times using 250111 of binding buffer. After the final wash the resin was 
resuspended in 30 pl of 2X loading buffer (125 mm Tris-HCI, pH 6.8; 4% [w/v] 
SDS; 1.4 M p-mercaptoethanol; 25% [v/v] glycerol; 0.1% [w/v] bromphenol 
blue) of which one-half was electrophoresed on 12.5% denaturing gels and 
processed as previously described (Leid, 1994; Leid, et al., 1992b). Some 
GST pull-down experiments were conducted as described above but with the 
addition of unlabeled, annealed oligonucleotides corresponding to ACO and 
DR1 PPREs to all incubations and wash buffers at a final concentration of 5 
fmol/gl. 
2.3.6.	  Differential protease sensitivity assays 
Two III  (10 fmols) of  in  vitro translated  [35S]P P A R AA B, 
[35S]PPARAAB/A448, or [35S]PPARAAB/0425 were preincubated in 7111 of 
binding buffer (as described in GST Pull-Down Experiments) containing 
either WY-14,643 (pirinixic acid), ETYA, LY-171883 (5-[4'-(4"-acetyl-3"­
hydroxy-2"-propylphenoxy)butyl]tetrazole), clofibrate (2-(4-chlorophenoxy)­
2-methylpropanoic acid ethyl ester), clofibric acid (2-(4-chlorophenoxy)-2­
methylpropanoic acid), or an equal volume of vehicle for 30 min. at 22°C. 
The final concentration of vehicle did not exceed 0.15% (v/v)  in any 
experiment conducted. Stock solutions of all ligands were prepared on the 
day of the experiment in dimethyl sulfoxide (WY-14,643 and LY-171883) or 
ethanol (ETYA, clofibric acid, and clofibrate).  DPSAs were initiated by 
addition of 1 0 of 10X stock solution of chymotrypsin in water and were 
allowed to proceed for 20 min. at 22°C.  Reactions were terminated by 
addition of one volume of 2X loading buffer (as described in GST Pull-Down 
Experiments).  Electrophoresis, autoradiography, and densitometric 36 
quantification were carried out as previously described (Leid, 1994; Leid, et 
al., 1992b). DPSAs conducted to determine the effect of heterodimerization 
with mRXRa were carried out essentially as described above except that 
[35S]methionine-labeled PPAR preparations were incubated with a 2-fold 
molar excess of in vitro translated mRXRa or unprogrammed lysate for 10 
min. at 22°C prior to addition of ligand. 
2.3.7.  Chemicals and reagents 
WY-14,643 was purchased from Chemsyn Science Labs (Lenexa, 
KS). LY-171883 and ETYA were obtained from BIOMOL (Plymouth Meeting, 
PA). Clofibric acid, clofibrate, and chymotrypsin were purchased from Sigma 
(St. Louis, MO). 
2.4.  Results 
2.4.1.  Introduction 
Carboxy terminal truncation mutants of PPARAAB were constructed to 
define regions of the receptor required for interaction with RXR and to 
determine if diverse ligands require distinct mPPARa structural features. 
Based on the crystal structures of RXRa (Bourguet, et al., 1995; Renaud, et 
al., 1995) and retinoic acid receptor 7 (RARy, Renaud, et al., 1995) LBDs and 
the predicted structural similarity of these receptors to mPPARa (Wurtz, et al., 
1996) and (data not shown), two PPARAAB carboxy terminal truncation 
mutants were prepared: 1) PPARAAB/A448, that lacks a portion of putative 
helix H11 and all of helix H12, and 2) PPARAAB/A425, that lacks putative 
helices H10-H12 (see Fig. 2.1A). Because both carboxy terminal truncation 37 
mutants lack the core of the putative ligand-dependent transcriptional 
activation function (AF-2, Wurtz, et al., 1996), neither would be expected to 
activate transcription in a ligand-dependent manner. 
2.4.2.  mPPARa carboxyl-terminal truncation mutants define
PPAR-RXR heterodimerization interface 
EMSAs were conducted to compare the ability of PPARAA B, 
PPARAAB/A448, and PPARAAB/A425 to bind two degenerate DR1 probes: a 
DR1 retinoid responsive element described previously (Mader, et al., 1993) 
and a peroxisome proliferator-activated response element (PPRE) identified 
in the promoter region of the rat acyl-CoA oxidase gene (ACO-PPRE) that 
confers peroxisome proliferator inducibility on this gene (Tugwood, et al., 
1992). While none of the PPAR receptors bound either probe alone (Fig. 2.2, 
lanes 3, 5, 7, 11, 13, and 15), addition of in vitro translated mRXRa resulted 
in mRXRa-PPARAAB (Fig. 2.2, lanes 4 and 12) and mRXRa-PPARAAB/A448 
(Fig. 2.2, lanes 6 and 14) heterodimeric complex formation on both probes. 
PPARAAB/0425 did not interact with mRXRa on either probe (Fig. 2.2, lanes 
8 and 16).  RXR homodimeric complexes have previously been 
demonstrated to bind DR1 response elements (Durand, et al.,  1992; 
Lehmann, et al., 1993; Leid, 1994; Mangelsdorf, et al., 1991; Zhang, et al., 
1992b) and indeed such complexes are observed in our binding assays on 
the DR1 but not the ACO-PPRE probe (Fig. 2.2, compare lanes 2 and 10). 
The efficiency of mRXRa-PPARAAB/A448 complex formation on both probes 
was reduced approximately 2-fold relative to that of mRXRa-PPARAA B 
suggesting that mPPARa residues 448-468 contribute to the stability of the 
heterodimeric complex but are not absolutely required for complex formation 38 
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Fig. 2.1. mPPARa carboxy terminal truncation mutants and PPAR 
ligands. A, Schematic representation of hRARy, hRXRa, and mPPARa 
carboxy terminal regions. H9-H12 represent a helical regions within the LBD 
of hRARy (Renaud et al., 1995) and hRXRa (Bourguet et al., 1995). The 
carboxy terminal mPPARa residues of PPARAAB/0448 and PPARAAB/A425 
(1447 and P424, respectively) are indicated by arrows. The linear alignment of 
mPPARa LBD with that of hRAR-y and hRXRa was adapted from (Wurtz et al., 
1996). B, Structures of the PPAR activators used in this study. 39 
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Fig. 2.2. PPAR/RXR heterodimeric complex formation on a DR1 and
ACO-PPRE. The filled and open arrows indicate positions of RXR
homodimeric complexes and PPAR/RXR heterodimeric complexes, 
respectively. Lanes 1 and 9 represent non-specific binding activity present in 
unprogrammed reticulocyte lysate (not indicated by an arrow). Experiments 
and gel processing were carried out as described in  "Materials and 
Methods". 40 
and DNA binding.  However, truncation of an additional 23 mPPARa 
carboxy-terminal residues (amino acids 425-468; PPARAAB/0425) abolished 
the ability of the receptor to interact with mRXRa on either probe (Fig. 2.2, 
lanes 8 and 16). 
Protein-protein interaction experiments were carried out to investigate 
the ability of PPARa carboxy terminal truncation mutants to interact with RXR 
independently of DNA binding. GST-mRXRa fusion protein, immobilized on 
glutathione sepharose, was used in standard GST pull-down experiments for 
this purpose.  In vitro translated [35S]PPARAAB and [35S]PPARAAB/A448 
both interacted with GST-mRXRa (Fig. 2.3, lanes 4 and 5) while an 
interaction between [35S]PPARAAB/0425 and GST-mRXRa was not detected 
(Fig. 2.3, lane 6). The efficiency of [35S]PPARAAB/A448 interaction with 
GST -mRXRa was reduced approximately 2-fold relative to that of 
[35S]PPARAAB with GST-mRXRa in agreement with DNA binding 
experiments described above. No interactions between any of the PPAR 
receptor proteins and an immobilized GST protein (Fig. 2.3, lanes 7-9) or 
glutathione sepharose alone were observed (data not shown). Additionally, 
results from experiments conducted in the presence of unlabeled response 
elements, identical to those used in DNA binding assays (see above), were 
indistinguishable from those described above (data not shown). 
2.4.3.  The sensitivity of mPPARa to chymotryptic digestion is
altered by interaction with ligands that activate the receptor 
We have adapted a differential protease sensitivity assay (DPSA, see 
Leid, 1994) for use with [35S]P PARAAB to address the possibility that 
peroxisome proliferators and related compounds (see Fig. 2.1E3) interact with 
and alter the protease sensitivity of the receptor. Digestion of [35S]PPARAAB 41 
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Fig. 2.3. PPAR interactions with an immobilized GST-mRXRa 
fusion protein. GST-mRXRa (lanes 4-6) or GST (lanes 7-9) immobilized on 
glutathione sepharose beads were incubated with [35SJPPARAAB, 
[35S]PPARAAB/A448, and [35S]PPARAAB/A425 (-100 fmol) and extensively 
washed as described in  "Materials and Methods". The beads were 
resuspended in 30111 of 2X SDS sample buffer, boiled, and 150 was loaded 
on a 12.5% SDS polyacrylamide gel. Input lanes represent -10 fmol of 
[35S]PPARAAB, [35S]PPARAAB/A448, and [35S]PPARAAB/0425 (lanes 1-3, 
respectively). Electrophoresis and gel processing were carried out as 
described in "Materials and Methods". The migration of Bio-Rad prestained 
low molecular weight standards is indicated. 42 
with increasing concentrations of chymotrypsin in the presence of 100 gm LY­
171883, ETYA, or WY-14,643 (Fig. 2.4A, lanes 11-13, 14-16, and 17-19, 
respectively) resulted in the appearance of protease resistant fragments of 
approximately 33, 31, and 27 kDa, referred to hereafter as PF33, PF31, and 
PF27, respectively.  Clofibric acid and clofibrate, when examined at 
concentrations of 100 gm, resulted in very weak signals (data not shown), 
therefore, these PPAR ligands were examined at concentrations of 1mm. 
While clofibric acid clearly induced formation of PF33, PF31, and PF27 (Fig. 
2.4A, lanes 5-7), clofibrate only weakly induced formation of these proteolytic 
fragments (Fig. 2.4A, lanes 8-10).  The glucocorticoid receptor ligand, 
dexamethasone, had no effect on the proteolytic sensitivity of [35S]PPARAAB 
at concentrations up to 1 mm (data not shown).  Moreover, none of the 
mPPARa activators examined affected the protease sensitivity of other 
nuclear receptors such as mRXRa (data not shown), indicative of the 
specificity of these observations.  These results suggest that mPPARa 
undergoes a ligand-induced conformational change upon interaction with 
compounds previously demonstrated to activate the receptor in transient 
transfection experiments (Hsu, et al., 1995; lssemann and Green, 1990; 
Kliewer, et al., 1994; Kliewer, et al., 1995). Chymotrypsin-resistant fragments 
induced by clofibric acid, clofibrate, LY-171883, ETYA, and WY-14,643 
appear to be indistinguishable suggesting that a similar change within 
mPPARa may be induced by all five PPAR activators. The following rank 
order of efficacy of the five PPAR activators for induction of PFs within 
PPARAAB, at concentrations of 100 1M, was determined using quantitative 
densitometric scanning of autoradiographs from DPSAs (as previously 
described in Leid, 1994; data not shown): 
WY-14,643 » ETYA > LY-171883 » clofibric acid > clofibrate. 43 
Fig. 2.4. Ligand-induced structural alterations within PPAR. A,
[35S]PPARAAB subjected to DPSA. [35S]PPARAAB (-10 fmol) was 
preincubated for 30 min. at room temperature with either vehicle (lanes 1-4), 
1 mM clofibric acid (CFA; lanes 5-7), 1 mM clofibrate (CLO; lanes 8-10), 100 
[iM LY-171883 (lanes 11-13), 100 p.M ETYA (lanes 14-16), or 10011M WY­
14,643 (lanes 17-19) before addition of chymotrypsin (final concentrations of 
75, 150, and 300 pig/m1 in lanes 2-4, 5-7, 8-10, 11-13, 14-16) or water (lane 
1). Proteolytic digestions were carried out at room temperature for 20 min., 
after which time samples were denatured and electrophoresed on a 12.5% 
SDS polyacrylamide gel. Gels were processed as described in "Materials 
and Methods". B, [35WPARAAB/0448 subjected to DPSA. Preincubations, 
electrophoresis, and gel processing were carried out as described in A. Final 
concentrations of chymotrypsin were 20, 50, and 100 µg /ml in lanes 2-4, 5-7, 
8-10, 11-13, 14-16. C, [35S] P PARAABL0425 subjected  to DPSA. 
Preincubations,  protease concentrations,  electrophoresis, and gel 
processing were carried out as described in B. Arrows throughout the figure 
indicate position of proteolytic fragments and migration of Bio-Rad prestained 
low molecular weight standards is indicated. Note that unproteolyzed
receptor preparations incubated with vehicle alone (lane  1), were 
indistinguishable from those incubated with clofibric acid, clofibrate, LY­
171883, ETYA, or WY-14,643 (data not shown). Clofibric acid and clofibrate 
are abbreviated as CFA and CLO, respectively. 44 
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DPSAs  were  carried  out  using  truncation  mutants 
[35S]PPARAAB/A448 and [35S]PPARAAB/A425 (see Fig. 2.1A) toward the 
goal  of determining  if  distinct  receptor regions are required  for 
responsiveness to structurally-diverse PPAR ligands.  A clear differential 
proteolytic pattern was observed with [35S]PPARAAB/0448 in the presence of 
1 mM clofibric acid, 100 p.m LY-171883, and 100 lim WY-14,643 (Fig. 2.4B, 
lanes 5-7, 11-13, and 17-19, respectively) and a weaker but detectable 
differential proteolytic pattern was observed with 1 mM clofibrate (Fig. 2.4B, 
lanes 8-10).  Ligand-induced alterations in the protease sensitivity of 
[35S]P PA RAAB and [35S]PPARAAB/0448 appeared to be qualitatively 
indistinguishable for all ligands examined except that the proteolytic 
fragments derived from [35S]PPARAAB/A448 were of smaller mass reflecting 
the truncation of 21 carboxy terminal amino acids (see arrows in Fig. 2.4B; 
termed PF33A448, PF31A448, and PF27A448).  However, in contrast to 
[35S]PPARAAB, the protease sensitivity of [35S]PPARAAB/A448 was only 
weakly affected by ETYA (Fig. 2.4B, lanes 14-16). The following rank order 
of the five PPAR activators for induction of PFs within PPARAAB/0448, at 
concentrations of 100 11M, was determined using quantitative densitometric 
scanning (data not shown): 
WY-14,643 » LY-171883 » clofibric acid > ETYA = clofibrate. 
These results suggest that the most carboxy-terminal 21 mPPARcc 
residues (448-468 corresponding to all of putative helix 12 and a portion of 
helix 11; see Fig. 2.1A) are important for mPPARa responsiveness to ETYA. 
With the possible exception of WY-14,643, [35S]PPARAAB/A425 did not 
exhibit a differential proteolytic pattern in the presence of any PPAR ligands 
examined (Fig. 2.4C) suggesting that the extreme carboxy terminal mPPARoc 
amino acids may be required for responsiveness to many PPAR ligands. 46 
2.4.4. Induction of proteolytic fragments is dependent on
ligand concentration 
DPSAs were conducted using [35S]PPARAAB at a constant 
chymotrypsin concentration and increasing concentrations of PPAR ligands 
(WY-14,643, ETYA, LY-171883, CFA; see Fig. 2.1B) to determine the 
dependence of PF33, PF31, and PF27 on ligand concentration. Induction of 
all proteolytic fragments from [35S]PPARAAB was clearly ligand-dependent in 
all cases (Fig. 2.5A-D) and the relative potencies with which these 
compounds induced [35S]PPARAAB conformational change in vitro was 
generally consistent with previously reported transcriptional activation 
studies (Hsu, et al., 1995; Issemann and Green, 1990; Kliewer, et al., 1994; 
see also Discussion). 
2.4.5.  PPAR Activator-Induced Chymotryptic Sensitivity of 
m PPAR a is not Altered by Heterodimerization with mRXRa 
Because PPARa has been demonstrated to heterodimerize with RXR 
(Gearing, et al., 1993; Issemann, et al., 1993a; Keller, et al., 1993; Kliewer, et 
al., 1992; see Figs. 2.2 and 2.3), DPSAs were conducted to examine the 
effects of heterodimerization with mRXRa on the induction of [35S]PPARAAB 
proteolytic fragments by WY-14,643.  DPSAs, in  the presence of 
unprogrammed lysate or in vitro translated mRXRa, were carried out at a 
constant protease concentration and increasing concentrations of WY­
14,643.  Interaction with mRXRa did not alter the protease sensitivity of 
unliganded  [35S] P PARAAB (Fig. 2.6A, compare lanes 2 and 6) or 
[35S]PPARAAB/A448 (Fig. 2.6B, compare lanes 2 and 6).  In addition, the 
concentration dependence of WY-14,643 on the induction of proteolytic C 
47 
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Fig. 2.5. PPAR activator dose response curves with PPARAAB. A,
[35S]PPARAAB subjected to DPSA in  the presence of increasing 
concentrations of WY-14,643. [35S]PPARAAB (- 10 fmol) was preincubated 
for 30 min. at room temperature with either vehicle (lanes 1-2) or increasing 
concentrations of WY-14,643 (1-100,000 nM in log units, lanes 3-8). Water 
(lane 1) or chymotrypsin, at a final concentration of 150 ig /ml (lanes 2-9) was 
added and the reaction allowed to proceed for 20 min. at room temperature. 
Electrophoresis and gel processing were as described in  Fig. 4.  B, 
[35S]PPARAAB subjected to DPSA in  the presence of increasing 
concentrations of ETYA. Experiments were conducted as  in  A. C, 
[35S]PPARAAB subjected to DPSA in  the presence of increasing 
concentrations of LY-171883. Experiments were conducted as in A. D, 
[35S]PPARAAB subjected to DPSA in  the presence of increasing 
concentrations of clofibric acid (CFA). Experiments were conducted as in A, 
except the additional lane 10, which represents a final concentration of 1 
mM. Migration of proteolytic fragments and Bio-Rad prestained low 
molecular weight standards are indicated. 48 
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Fig. 2.6. Effect of heterodimerization with RXR on PPAR ligand­
induced structural alterations. A, [35S]PPARAAB subjected to DPSA in 
the presence of increasing concentrations of WY-14,643 (1-100,000 nM in 
log units; lanes 2-5 and lanes 6-9) in the absence of RXR (lanes 1-5) and 
presence of RXR (lanes 6-9). Experiments were conducted as described in 
Fig. 5 A and in "Materials and Methods". B, [35S]PPARAAB/A448 subjected to 
DPSA in the presence of increasing concentrations of WY-14,643 (1-100,000 
nM in log units; lanes 2-5 and lanes 6-9) in the absence of RXR (lanes 1-5) 
and presence of RXR (lanes 6-9). Experiments were conducted as described 
in A except the final concentration of chymotrypsin was 50 µg /ml. Note that in 
A and B the amount of lysate was kept constant in all samples by addition of 
unprogrammed reticulocyte lysate. Migration of proteolytic fragments and 
Bio-Rad prestained low molecular weight standards are indicated. 49 
fragments derived from either receptor did not differ noticeably in the 
presence of mRXRa (compare lanes 2-5 with lanes 6-9 of Fig. 2.6A and B, 
respectively).  Similar results were observed for both [35S]PPARAAB and 
[35S]PPARAAB /A448 when using the PPAR ligands clofibric acid, clofibrate, 
LY-171883, and ETYA (data not shown). Moreover, the rank order of efficacy 
of the five compounds tested for induction of PFs within PPARAAB and 
PPARAAB/A448 did not differ from that stated above (data not shown). 
Therefore, heterodimerization with mRXRa does not appear to influence, 
positively or negatively, the capacity of mPPARa to bind PPAR activators and 
undergo ligand-induced conformational changes. [35S]PPARAAB/A425 was 
not examined in these experiments due the inability of this receptor mutant to 
interact with mRXRa (Figs. 2.2 and 2.3) or bind ligand (Fig. 2.4C). 
2.5.  Discussion 
PPARs, like other receptor proteins within the nuclear receptor 
superfamily, exhibit a conserved subdivision of receptor regions referred to 
as A/B, C, D, and E/F (Krust, et al., 1986, reviewed in Green and Chambon, 
1988; Leid, et al., 1992a; Mangelsdorf, et al., 1995; Tsai and O'Malley, 1994). 
Experiments conducted with various chimeric receptor proteins composed of 
putative PPARa ligand binding domains (LBDs) fused to heterologous DNA 
binding domains from estrogen (Dreyer, et al., 1992; lssemann and Green, 
1990) and glucocorticoid (Gott licher, et al., 1992) receptors (ER and GR, 
respectively), bacterial tetracycline repressor (Yu, et al., 1995), and GAL4 
(Forman, et al., 1995a; Kliewer, et al., 1995; Lehmann, et al., 1995) have 
demonstrated the requirement for a large portion of the carboxy-terminus of 
PPARs (D and E/F regions as defined in Issemann and Green, 1990) for 50 
ligand-responsive transcriptional activation.  Results presented herein define 
overlapping regions within the carboxy-terminus of mPPARa (amino acids 
425-468) that are required for heterodimerization with mRXRa an d 
responsiveness to PPAR ligands.  Both functions are subserved by 
functionally homologous regions in several other nuclear receptors (Leid, et 
al., 1992b; Wurtz, et al., 1996) and may correspond to structurally conserved 
motifs (Wurtz, et al., 1996). 
Our results indicate that the extreme carboxy terminal amino acids of 
mPPARa are required for formation of PPAR/RXR heterodimeric complexes 
both in solution and bound to DR1 and ACO-PPRE probes. This finding is in 
agreement with a previous study that characterized a hPPARa point mutation 
(Leu433-->Arg corresponding to the same residue in mPPARa) which 
abolished heterodimerization with RXR (Juge-Aubry, et al., 1995) thus 
illustrating a critical role for this region (which is deleted in PPARAAB/A425). 
A putative leucine zipper-like heptad repeat, located between residues 426­
433 of mouse, human, and rat PPARa, has been postulated to mediate 
heterodimerization with RXR (Juge-Aubry, et al., 1995).  Truncation of 
mPPARa to amino acid 447 (PPARAAB/A448) gave rise to a receptor protein 
that was capable of interacting with RXR and binding to DR1 and ACO-PPRE 
probes, albeit at a 2-fold decreased efficiency as compared to a receptor 
protein with an intact carboxy terminus (PPARAAB). Considered together, 
these results suggest that the mPPARa dimerization interface contains at 
least Leu433, which is 100% conserved across all PPAR subtypes (Juge-
Aubry, et al., 1995), data not shown), and extends through at least 11e447.  In 
addition to heterodimerizing with RXR, PPARs have been reported to interact 
with thyroid hormone receptor (TR, Bogazzi, et al., 1994) and, more recently, 
Miyata et. al. reported that mPPARa interacts with a third member of the 51 
nuclear receptor superfamily, the orphan receptor LXRa (Miyata, et al., 
1996).  Therefore,  it appears that there may be physiologically relevant 
cross-talk between PPARs and signaling pathways mediated by other 
nuclear receptors.  It will be of interest to determine if other nuclear receptors 
interact with PPARs through distinct or common heterodimeric protein 
interfaces and if these protein-protein interactions and/or the functional 
capacities of the involved receptors are allosterically regulated by DNA 
binding as previously demonstrated for other nuclear receptors (Forman, et 
al., 1995b; Kurokawa, et al., 1994). 
PPAR activators constitute a chemically diverse group of compounds 
in which the most obvious common structural elements are an acidic group 
(free carboxyl group, a metabolically labile derivative thereof, or a bioisostere 
such as a tetrazole or sulfonamide moiety) and a TC electron-rich region 
(aromatic ring or series of alkenes or alkynes; see also Lewis and Lake, 
1993).  When considering the structural diversity exhibited by these 
compounds, it seems possible that the molecular determinants of mPPARa 
interaction with each ligand or class of ligands may be distinct. Indeed, our 
results  indicate  that  distinct mPPARa regions  are  required  for 
responsiveness to different PPAR activators. While PPARAAB is responsive 
to WY-14,643, ETYA, LY-171883, clofibric acid, and clofibrate, as detected by 
DPSAs, deletion of mPPARa residues 448-468 (PPARAAB/A448) severely 
compromises responsiveness to ETYA but not other PPAR ligands.  The 
distal carboxy terminal amino acids of mPPARa that are deleted in 
PPARAAB/A448 correspond to part (H12) of the region that has been 
proposed to stabilize ligand-receptor interactions with hRARy by functioning 
as a "lid" on the ligand binding cavity (Renaud et al, 1995; Wurtz et al, 1996). 
The greatly reduced efficacy with which ETYA induced PPARAAB/A448 52 
conformational change  relative  to PPARAAB suggests that the 
hydrophobicity of putative H12 may play a critical role in the stabilization of 
ETYA binding, perhaps owing to the unusually extended structure of this 
compound.  Truncation of mPPARa residues 425-468 (PPARAAB/A425) 
gave rise to a receptor protein which was slightly responsive to WY-14,643 
but unresponsive to all other PPAR ligands examined. In addition to deletion 
of putative helix H12, PPARAAB/0425 also lacks putative helices H10 and 
H11, encompassing a region that has been proposed to form one side of the 
nuclear receptor ligand binding pocket (Wurtz, et al., 1996), which may 
explain the inactivity of this mutant in DPSAs. However, we cannot presently 
rule out the possibility that the inactivity of PPARAAB/A425 is due to improper 
protein folding and/or detrimental structural distortions outside the deleted 
region. Nonetheless, it is clear that mPPARa residues 448-468 are important 
for ligand binding and/or conformational change induced by ETYA while 
being dispensable for responsiveness to other PPAR ligands supporting the 
hypothesis that distinct mPPARa receptor regions may be required for 
interaction with structurally dissimilar PPAR activators. 
Recently, several synthetic antidiabetic thiazolidinediones (Forman, et 
al., 1995a; Kliewer, et al., 1995; Lehmann, et al., 1995) and 15-deoxy-Al2,14­
prostaglandin J2 (Forman, et al., 1995a; Kliewer, et al., 1995) have been 
shown to bind directly to the ligand binding domain of the mouse PPAR-y. 
Direct binding of any compounds to PPARa subtypes, however, has not been 
demonstrated. lssemann et al specifically report the lack of [3H]nafenopin 
binding by mPPARa which may be due to both a low affinity of nafenopin for 
mPPARa and a large amount of endogenous binding activity in the cell lines 
tested (lssemann and Green, 1990).  In the current study, DPSA 
methodology was adapted to facilitate detection of ligand interactions with 53 
mPPARa. DPSAs have been demonstrated to be a useful method for 
detection of ligand-induced conformational change within the nuclear 
receptor superfamily (Allan, et al., 1992a; Allan, et al., 1992b; Beekman, et 
al., 1993; Bhat, et al., 1993; Fritsch, et al., 1993; Fritsch, et al., 1992; Keidel, et 
al., 1994; Leid, 1994; Leng, et al., 1993; Simons, et al., 1989; Vegeto, et al., 
1992; Yao, et al.,  1993).  The differential sensitivity of liganded and 
unliganded receptors is likely related to ligand-induced stabilization of one or 
more receptor conformations that exhibit sensitivity to proteolytic digestion 
different from that of unliganded receptor. Although DPSAs yield data that 
are somewhat less amenable to quantitative analyses than radioligand 
binding experiments, an advantage of the former is the ability to detect low 
affinity ligand-receptor interactions.  All mPPARa activators tested induced 
mPPARa conformational change in vitro albeit it with varying potencies. 
However, the relative potencies of these compounds with regard to induction 
of PPARAAB conformational change in vitro is generally consistent with 
previously reported transcriptional activation studies utilizing mPPARa: WY­
14,643 » ETYA > LY-171883 » Clofibric acid (Hsu, et al., 1995; lssemann 
and Green, 1990; Kliewer, et al., 1994). ETYA, a potent activator of Xenopus 
PPARa (Keller, et al., 1993), was a substantially weaker ligand than WY­
14,643 in the in vitro studies employing PPARAAB described herein (Fig. 
2.5). Hsu and co-workers also reported that ETYA was approximately ten­
fold weaker than WY-14,643 as an activator of mPPARa in transient 
transfection experiments (Hsu, et al., 1995) suggesting that the enhanced 
potency of ETYA reported by Keller and co-workers (Keller, et al., 1993) may 
be conferred by species-specific receptor activity, cell-specific factors, and/or 
mechanism(s) other than direct binding of this arachidonic acid analog to the 
receptor. 54 
It has been hypothesized that Hsp72, which has been demonstrated to 
interact directly with rat PPARa (rPPARa), may bind PPAR activators and, in 
turn, allosterically activate the associated receptor protein (Huang, et al., 
1994).  Presently, we cannot exclude this possibility, however, results from 
DPSAs in which mPPARa carboxy terminal truncation mutants were used 
suggest an alternative molecular mechanism. For example, deletion of 21 
mPPARa carboxy terminal amino acids (PPARAAB/A448) compromises the 
responsiveness of the receptor to ETYA but not other PPAR ligands.  If Hsp72 
binds these ligands directly and allosterically transduces a signal that alters 
the conformation of mPPARa, it seems unlikely that this process would be 
attenuated by carboxy terminal truncation of mPPARa unless the deleted 
amino acids are required for mPPARa-Hsp72 interaction.  In such a case, 
one would expect this truncation to abolish responsiveness to all ligands. Of 
course, it is possible that some ligands selectively interact with mPPARa, 
Hsp72 or both proteins in the context of a mPPARa-Hsp72 complex. The 
latter possibility would be reminiscent of ecdysone receptor in which 
ecdysone binding activity is associated with a complex of ecdysone receptor 
and ultraspiracle (Yao, et  al.,  1993).  In any event, ligand-induced 
conformational change likely underlies the molecular basis of ligand 
activation of the putative mPPARa transcriptional activation function, AF-2 
and identification of ligand-induced mPPARa proteolytic fragments will be of 
critical importance to our understanding of the dynamic process of PPAR 
activation by ligands and interaction of liganded receptor with putative 
transcriptional intermediary factors (TIFs). 55 
2.6.  Note added in proof
 
Consistent with some of the data presented herein, Devchand et al 
recently published results demonstrating direct binding of [3H]leukotriene B4 
to a bacterially expressed and purified GST-Xenopus PPARa fusion protein 
and inhibition of this binding by unlabeled WY-14,643 (Devchand, P. R., 
Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J. and Wahli, W. (1996) 
Nature 384, 39-43). 
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The abbreviations used are: PPAR, peroxisome proliferator-activated 
receptor; mPPARa, murine peroxisome proliferator-activated receptor a; 
ETYA,  5,8,11,14-eicosatetraynoic  acid;  8-[S]-HETE,  8-[S]­
hydroxyeicosatetraenoic acid; DR1, direct repeat separated by one 
nucleotide; RXR, retinoid X receptor; 9-cis-RA, 9-cis-retinoic acid; PPRE, 
peroxisome proliferator-activated response element; hPPARa, human 
peroxisome proliferator-activated receptor a; DPSA, differential protease 
sensitivity  assay; mRXRa, murine retinoid X receptor a;  EMSA, 
electrophoretic mobility shift assay; ACO-PPRE, acyl Co-A oxidase 
peroxisome  proliferator  response element;  IPTG,  isopropyl  P-D­
thiogalactopyranoside; LBD, ligand binding domain; RARy, retinoic acid 
receptor y; PF, proteolytic fragment; ER, estrogen receptor; GR, glucocorticoid 
receptor; TR, thyroid hormone receptor; rPPARa, rat PPARa; TIF, 
transcriptional intermediary factor. 56 
2.8.  Acknowledgments 
We thank Ph. Kastner, P. Chambon, T. Lufkin, J. D. Tugwood, S. 
Green, and W. Dougherty for plasmid constructs; R. McParland and B. 
Robbins for oligonucleotide synthesis; B. Hettinger-Smith and J. E. Ishmael 
for useful discussions and critical review of the manuscript; and the 
Communications Media Center for figure preparation. 
2.9.  References 
Allan, G. F., Leng, X., Tsai, S. Y., Weigel, N. L., Edwards, D. P., Tsai, M.-J. and 
O'Malley, B. W. (1992a). Hormone and antihormone induce distinct 
conformational changes which are central to steroid receptor activation. J. 
Biol. Chem. 267, 19513-19520. 
Allan, G. F., Tsai, S. Y., Tsai, M.-J. and O'Malley, B. W. (1992b). Ligand-
Dependent Conformational Changes in the Progesterone Receptor Are 
Necessary for Events That Follow DNA Binding. Proc. Natl. Acad. Sci. U. S. 
A. 89, 11750-11754. 
Bardot, 0., Aldridge, T. C., Latruffe, N. and Green, S. (1993). PPAR-RXR 
heterodimer activates a peroxisome proliferator response element upstream 
of the bifunctional enzyme. Biochem. Biophys. Res. Commun. 192, 37-45. 
Beekman, J. M., Allan, G. F., Tsai, S. Y., Tsai, M.-J. and O'Malley, B. W. 
(1993). Transcriptional activation by the estrogen receptor requires a 
conformational change in the ligand binding domain. Mol.  Endocrinol. 10, 
1266-1274. 
Bhat, M. K., Parkison, C., Mcphie, P., Liang, C. M. and Cheng, S. Y. (1993). 
Conformational Changes of Human beta-1-Thyroid Hormone Receptor 
Induced by Binding of 3,3',5-Triiodo-L-thyronine. Biochem. Biophys.  Res. 
Commun. 195, 385-392. 
Bogazzi,  F.,  Hudson, L.  D. and Nikodem, V.  M. (1994). A novel 
heterodimerization partner for thyroid hormone receptor. Peroxisome 
proliferator-activated receptor. J. Biol. Chem. 269, 11683-11686. 
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. and Moras, D. (1995). 
Crystal structure of the ligand-binding domain of the human nuclear receptor 
RXRec. Nature 375, 377-382. 57 
Brun, R. P., Tontonoz, P., Forman, B. M., Ellis, R., Chen, J., Evans, R. M. and 
Spiegelman, B. M. (1996). Differential activation of adipogenesis by multiple 
PPAR isoforms. Genes Dev. 10, 974-984. 
Castelein, H., Gulick, T., Declercq, P. E., Mannaerts, G. P., Moore, D. D. and 
Baes, M. I. (1994). The peroxisome proliferator-activated receptor regulates 
malic enzyme gene expression. J. Biol. Chem. 269, 26754-26758. 
Dreyer, C., Keller, H., Mahfoudi, A., Laudet, V., Krey, G. and Wahli, W. (1993). 
Positive regulation of the peroxisomal 13-oxidation pathway by fatty acids 
through activation of peroxisome proliferator-activated receptors (PPAR). 
Biol. Cell 77, 67-76. 
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G. and Wahli, W. (1992). 
Control of the peroxisomal 13-oxidation pathway by a novel family of nuclear 
hormone receptors. Cell 68, 879-887. 
Durand, B., Saunders, M., Leroy, P., Leid, M. and Chambon, P. (1992). All-
trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by 
RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Ce1171, 73­
85. 
Evans, R. M. (1988). The steroid and thyroid hormone receptor superfamily. 
Science 240, 889-895. 
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M. and 
Evans, R. M. (1995a). 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for 
the adipocyte determination factor PPAR gamma. Ce// 83, 803-812. 
Forman, B. M., Umesono, K., Chen, J. and Evans, R. M. (1995b). Unique 
response pathways are established by allosteric interactions among nuclear 
hormone receptors. Ce1181, 541-550. 
Fritsch, M., Anderson, I. and Gorski, J. (1993). Structural characterization of 
the trypsinized estrogen receptor. Biochemistry 32, 14000-14008. 
Fritsch, M., Leary, C. M., Furlow, J. D., Ahrens, H., Schuh, T. J., Mueller, G. C. 
and Gorski, J. (1992). A ligand-induced conformational change in the 
estrogen receptor is localized in the steroid binding domain. Biochemistry 
31, 5303-5311. 
Gearing, K. L., Gottlicher, M., Teboul, M., Widmark, E. and Gustafsson, J.-A. 
(1993). Interaction of the peroxisome-proliferator-activated receptor and 
retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 90, 1440-1444. 
Gottlicher, M., Widmark, E., Li, Q. and Gustafsson, J.-A. (1992). Fatty acids 
activate a chimera of the clofibric acid-activated receptor and the 
glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 89, 4653-4657. 58 
Green, S. (1995). PPAR: a mediator of peroxisome proliferator action. 
Mutation Research 333,  101-109. 
Green, S. and Chambon, P. (1988). Nuclear receptors enhance our 
understanding of transcription regulation. Trends in Gen. 4, 309-314. 
Hsu, M.-H., Palmer, C. N., Griffin, K. J. and Johnson, E. F. (1995). A single 
amino acid change in the mouse peroxisome proliferator-activated receptor 
alpha alters transcriptional responses to peroxisome proliferators. Mol. 
Pharmacol. 48,  559-567. 
Huang, Q., Alvares, K., Chu, R., Bradfield, C. A. and Reddy, J. K. (1994). 
Association of peroxisome proliferator-activated receptor and Hsp72. J. Biol. 
Chem. 269, 8493-8497. 
Issemann, I. and Green, S. (1990). Activation of a member of the steroid 
receptor superfamily by peroxisome proliferators. Nature 347, 645-650. 
Issemann, I., Prince, R. and Green, S. (1992). A role for fatty acids and liver 
fatty acid binding protein in peroxisome proliferation? Biochem. Soc. Trans. 
20, 824-827. 
Issemann, I., Prince, R. A., Tugwood, J. D. and Green, S. (1993a). The 
peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is 
activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 
11, 37-47. 
Issemann, I., Prince, R. A., Tugwood, J. D. and Green, S. (1993b). The 
retinoid X receptor enhances the function of the peroxisome proliferator 
activated receptor. Biochimie 75, 251-256. 
Juge-Aubry, C. E., Gorla-Bajsczczak, A., Pernin, A., Lemberger, T., Wahli, W., 
Burger, A. G. and Meier, C. A. (1995). Peroxisome proliferator-activated 
receptor mediates cross-talkwith thyroid hormone receptor by competition for 
retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. J. 
Biol. Chem. 270, 18117-18122. 
Keidel, S., LeMotte, P. and Apfel, C. (1994). Different agonist- and 
antagonist-induced conformational changes in  retinoic acid receptors 
analyzed by protease mapping. Mol. Cell. Biol. 14, 287-298. 
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K. and Wahli, W. (1993). 
Fatty acids and retinoids control lipid metabolism through activation of 
peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. 
Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164. 
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., 
Mangelsdorf, D. J., Umesono, K. and Evans, R. M. (1994). Differential 59 
expression and activation of a family of murine peroxisome proliferator­
activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91, 7355-7359. 
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C. and 
Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome 
proliferator-activated  receptor gamma and  promotes  adipocyte 
differentiation. Cell 83, 813-820. 
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A. and Evans, R. M. 
(1992). Convergence of 9-cis retinoic acid and peroxisome proliferator 
signalling pathways through heterodimer formation of their receptors. Nature 
358, 771-774. 
Krust, A., Green, S., Argo, P., Kumar, V., Walter, P., Bornert, J. M. and 
Chambon, P. (1986). The chicken oestrogen receptor sequence: homology 
with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J. 
5, 891-897. 
Kurokawa, R., DiRenzo, J., Boehm, M., Sugarman, J., Gloss, B., Rosenfeld, M. 
G., Heyman, R. A. and Glass, C. K. (1994). Regulation of retinoid signalling 
by receptor polarity and allosteric control of ligand binding. Nature 371, 528­
531. 
Lake, B. G. (1995). Mechanisms of hepatocarcinogenicity of peroxisome-
proliferating drugs and chemicals. Ann. Rev. Pharmacol. Toxicol. 35, 483­
507. 
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., 
Fernandez-Salguero, P. M., Westphal, H. and Gonzalez, F. J. (1995). 
Targeted disruption of the a isoform of the peroxisome proliferator-activated 
receptor gene in mice results in abolishment of the pleiotropic effects of 
peroxisome proliferators. MoL Cell. Biol. 15, 3012-3022. 
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. 0., Willson, T. 
M. and Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high 
affinity ligand for peroxisome proliferator-activated receptor y. J. Biol. Chem. 
270, 12953-12956. 
Lehmann, J. M., Zhang, X.-K., Graupher, G., Lee, M. -O., Hermann, T., 
Hoffmann, B. and Pfahl, M. (1993). Formation of retinoid X receptor 
homodimers leads to repression of T3 response: hormonal cross talk by 
ligand-induced squelching. Mol. Cell. Biol. 13, 7698-7707. 
Leid, M. (1994). Ligand-induced alteration of the protease sensitivity of 
retinoid X receptor. J. Biol. Chem. 269, 14175-14181. 
Leid, M., Kastner, P. and Chambon, P. (1992a). Multiplicity generates 
diversity in the retinoic acid signalling pathways. Trends in Biochem. Sci. 17, 
427-433. 60 
Leid, M., Kastner, P., Lyons, R., Nakshatri, H., Saunders, M., Zacharewski, T., 
Chen, J.-Y., Staub, A., Garnier, J.-M., Mader, S. and Chambon, P. (1992b). 
Purification, cloning, and RXR identity of the He La cell factor with which RAR 
or TR heterodimerizes to bind target sequences efficiently. Cell 68, 377-395. 
Leng, X., Tsai, S. Y., O'Malley, B. W. and Tsai, M.-J. (1993). Ligand­
dependent conformational changes in thyroid hormone and retinoic acid 
receptors are potentially enhanced by heterodimerization with retinoic X 
receptor. J. Steroid Biochem. Mol. Biol. 46, 643-661. 
Lewis, D. F. V. and Lake, B. G. (1993). Interaction of Some Peroxisome 
Proliferators with the Mouse Liver Peroxisome Proliferator-Activated 
Receptor (PPAR) A Molecular Modelling and Quantitative Structure-Activity 
Relationship (QSAR) Study. Xenobiotica 23, 79-96. 
Mader, S., Chen, J.-Y., Chen, Z., White, J., Chambon, P. and Gronemeyer, H. 
(1993). The patterns of binding of RAR, RXR and TR homodimers and 
heterodimers to direct repeats are dictated by the binding specificities of the 
DNA binding domains. EMBO J. 12, 5029-5041. 
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Shutz, G., Umesono, 
K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. and Evans, R. M. (1995). 
The nuclear receptor superfamily: the second decade. Cell 83, 835-839. 
Mangelsdorf, D. J., Umesono, M., Kliewer, S. A., Borgmeyer, U., Ong, E. S. 
and Evans, R. M. (1991). A direct repeat in the cellular retinol-binding protein 
type II gene confers differential regulation by RXR and RAR. Cell 66, 555­
561. 
Miyata, K. S., McCaw, S. E., Patel, H. V., Rachubinski, R. A. and Capone, J. P. 
(1996). The orphan nuclear hormone receptor LXRa interacts with the 
peroxisome proliferator-activated  receptor and inhibits peroxisome 
proliferator signalling. J. Biol. Chem. 271, 9189-9192. 
Muerhoff, A. S., Griffin, K. J. and Johnson, E. F. (1992). The peroxisome
proliferator-activated receptor mediates the induction of CYP4A6, a 
cytochrome P450 fatty acid w-hydoxylase, by clofibric acid. J. Biol. Chem. 
267, 19051-19053. 
Mukherjee, R., Low, L., Noonan, D. and McDonnell, D. P. (1994). Human and 
rat peroxisome proliferator-activated receptors (PPARs) demonstrate similar 
tissue distribution but different responsiveness to PPAR activators. J. Steroid 
Biochem. Mol. Biol. 51, 157-166. 
Parks, T. D., Leuther, K. K., Howard, E. D., Johnston, S. A. and Dougherty, W. 
G. (1994). Release of proteins and peptides from fusion proteins using a 
recombinant plant virus proteinase. Anal. Biochem. 216, 1-5. 61 
Renaud, J.-P., Rochel, N., Ruff, M., Vivant, V., Chambon, P., Gronemeyer, H. 
and Moras, D. (1995). Crystal structure of the RAR -y ligand binding domain 
bound to all-trans retinoic acid. Nature 378, 681-689. 
Rodriguez, J. C., Gil-Gomez, G., Hegardt, F. G. and Haro, D. (1994).
Peroxisome proliferator-activated receptor mediates induction of the 
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. 
J. Biol. Chem. 269, 18767-18772. 
Simons, S. S., Sistare, F. D. and Chakraborti, P. K. (1989). Steroid binding 
activity is retained in a 16-kDa fragment of the steroid binding domain of rat 
glucocorticoid receptors. J. Biol. Chem. 264, 14493-14497. 
Tontonoz, P.,  Hu, E. and Spiegelman, B. M. (1994). Stimulation of 
adipogenesis in fibroblasts by PPAR-gamma-2, a lipid-activated transcription 
factor. Cell 79, 1147-1156. 
Tsai, M.-J. and O'Malley, B. W. (1994). Molecular mechanisms of action of 
steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451­
486. 
Tugwood, J. D., lssemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L. 
and Green, S. (1992). The mouse peroxisome proliferator-activated receptor 
recognizes a response element in the 5' flanking sequence of the rat acyl 
CoA oxidase gene. EMBO J. 11, 433-439. 
Varanasi, U., Chu, R., Huang, Q., Catellon, R., Yeldani, A. V. and Reddy, J. K. 
(1996). Identification of a peroxisome proliferator-responsive element 
upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J. 
Biol. Chem. 271, 2147-2155. 
Vegeto, E., Allan, G. F., Schrader, W. T., Tsai, M.-J., McDonnell, D. P. and 
O'Malley, B. W. (1992). The mechanism of RU486 antagonism is dependent 
on the conformation of the carboxy-terminal tail of the human progesterone 
receptor. Cell 69, 703-713. 
Witzum, J. L. (1995) in The Pharmacological Basis of Therpaeutics, 
(Hardman, J. G., Gilman, A. G. and Limbird, L. E., Eds.), McGraw-Hill Inc., pp. 
892-894. 
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D. 
and Gronemeyer, H. (1996). A canonical structure for the ligand-binding 
domain of nuclear receptors. Nat. Struct. Biol. 3, 87-94. 
Yao, T. P., Forman, B. M., Jiang, Z., Cherbas, L., Chen, J. D., McKeown, M., 
Cherbas, P. and Evans, R. M. (1993). Functional ecdysone receptor is the 
product of EcR and Ultraspiracle genes. Nature 366, 476-479. 62 
Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., 
Brown, M. and Lazar, M. A. (1995). Differential activation of peroxisome 
proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975­
23983. 
Zhang, B., Marcus, S. L., Sajjadi, F. G., Alvares, K., Redyy, J. K., Subramani, 
S., Rachubinski, R. A. and Capone, J.  P. (1992a). Identification of a 
peroxisome proliferator-responsive element upstream of the gene encoding 
rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. 
Proc. Natl. Acad. Sci. U. S. A. 89, 7541-7545. 
Zhang, X.-K., Lehmann, J., Hoffmann, B., Dawson, M. I., Cameron, J., 
Graupner, G., Hermann, T., Tran, P. and Pfahl, M. (1992b). Homodimer 
formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 358, 
587-591. 63 
Chapter 3 
p300 Functions as a Coactivator for the Peroxisome Proliferator­
activated receptor  a 
Paul Dowell, Jane E. Ishmael, Dorina Avram, Valerie J. Peterson, Daniel J.
 
Nevrivy and Mark Leid
 
Program in Molecular and Cellular Biology
 
and Laboratory of Molecular Pharmacology, College of Pharmacy
 
Oregon State University
 
Corvallis, OR 97331
 
The Journal of Biological Chemistry 272: 33435-33443 
1997 64 
3.1.  Abstract 
The integrator protein, p300, was demonstrated to interact with mouse 
peroxisome proliferator-activated receptor a in a ligand-enhanced manner. 
The PPARa-interacting domain of p300 was mapped to amino acids 39-117 
which interacted strongly with PPARa but did not interact with retinoic acid 
receptor y or retinoid X receptor a. Amino acids within the extreme carboxyl 
terminus of PPARa as well as residues within the hinge region were required 
for ligand-dependent interaction  with p300.  p300 enhanced the 
transcriptional activation properties of PPARa and, therefore, can be 
considered a bona fide coactivator for this nuclear receptor.  These 
observations extend the group of p300-interacting proteins to include 
mPPARa and further characterize the molecular mechanisms of PPARa­
mediated transcriptional regulation. 
3.2.  Introduction 
Mammalian peroxisome proliferator-activated receptors (PPARs)1 are 
ligand-inducible transcription factors comprised of -a, -6 (also known as 
FAAR and NUC1), and -y subtypes which regulate expression of genes 
involved in lipid homeostasis (reviewed in Green, 1995; Schoonjans, et al., 
1996).  PPARs, along with the steroid, thyroid, and retinoid receptors all 
contain conserved protein regions that function in transcriptional activation, 
DNA binding, and homo- and/or heterodimerization  (reviewed  in 
Mangelsdorf, et al., 1995; Tsai and O'Malley, 1994). PPARs form a complex 
with the common heterodimeric partner, retinoid X receptor (RXR), thereby 
establishing a high affinity DNA binding complex that preferentially binds to a 
degenerate direct repeat of the canonical AGGTCA sequence separated by 
one base pair (DR1, Gearing, et al., 1993; Issemann, et al., 1993; Keller, et 65 
al., 1993; Kliewer, et al., 1992; Varanasi, et al., 1996).  The PPAR/RXR 
complex appears to be responsive to both PPAR and RXR ligands with 
synergistic activation profiles when ligands for both receptors are bound 
(Gearing, et al., 1993; lssemann, et al., 1993; Keller, et al., 1993; Kliewer, et 
al., 1992; Varanasi, et al., 1996). 
A variety of compounds have been identified as PPARa ligands 
including the synthetic fibric acid antihyperlipidemic drug, WY-14,643 
(Devchand, et al., 1996; lssemann and Green, 1990), and the naturally 
occuring compounds leukotriene B4 (Devchand, et al., 1996), linoleic, 
linolenic, and arachidonic acids (Forman, et al., 1997; Kliewer, et al., 1997). 
In addition to regulating genes involved in fatty acid oxidation (Bardot, et al., 
1993; Castelein, et al., 1994; lssemann, et al., 1992; Muerhoff, et al., 1992; 
Rodriguez, et al., 1994; Tugwood, et al., 1992; Varanasi, et al., 1996), PPARs 
have been shown to regulate the processes of peroxisome proliferation (Lee, 
et al., 1995b), adipogenesis (Brun, et al., 1996; Tontonoz, et al., 1994), and 
inflammation (Devchand, et al., 1996). Therefore, the PPAR family appears 
to play a prominent role  in modulating signal transduction pathways 
involving fatty acids, or derivatives thereof, as signaling molecules. 
The molecular mechanism(s) of transcriptional activation mediated by 
nuclear receptors, including PPAR/RXR complexes, has not been fully 
elucidated. However, evidence has accumulated indicating that ligand may 
promote a receptor conformation that favors interaction with transcriptional 
coactivators while promoting dissociation from receptor-associated 
corepressors, yielding a transcriptionally active complex (see Glass, et al., 
1997 and Horwitz, et al., 1996 and references therein).  The functional 
significance of receptor interactions with coactivators or corepressors and the 
resulting transcriptional activation or repression, respectively, may involve 66 
chromatin remodeling (reviewed in  Pazin and Kadonaga, 1997 and 
references therein). The coactivators CBP and p300 have been shown to 
interact with the histone acetyltransferase, P/CAF (Yang, et al., 1996), in 
addition to possessing intrinsic histone acetyltransferase activity (Bannister 
and Kouzarides, 1996; Ogryzko, et al.,  1996).  Conversely, receptor­
corepressor complexes have been shown to associate with histone 
deacetylase 1 (HDAC1, Heinzel, et al., 1997; Nagy, et al., 1997).  The 
resulting  covalent modification  of  histones,  either  acetylation  or 
deacetylation, may result in alterations within chromatin structure thereby 
facillitating or inhibiting, respectively, access of transcription factors and/or 
the core transcriptional machinery to DNA templates (reviewed in Wade and 
Wolffe, 1997).  It should also be noted that both receptors (Baniahmad, et al., 
1993; Ing, et al., 1992; Schulman, et al., 1995) and associated coactivators 
(Abraham, et al., 1993; Janknecht and Hunter, 1996b; Lee, et al., 1996) have 
been shown to interact directly with components of the basal transcription 
machinery suggesting that recruitment of the transcriptional apparatus, in 
addition to chromatin remodeling, may contribute to the molecular 
mechanisms of transcriptional activation.  It remains to be determined if 
additional mechanisms are operant and if so, the relative importance of these 
additional pathways. 
Two main families of transcriptional coactivators that interact with 
nuclear receptors have been identified: (1) The p300/CBP like proteins 
including CBP and p300 (Chakravarti, et al., 1996; Hanstein, et al., 1996; 
Kamei, et al., 1996; Yao, et al., 1996), and (2) the SRC-1 family of proteins 
which includes SRC-1 (Kamei, et al., 1996; Onate, et al., 1995; Yao, et al., 
1996), TIF2/GRIP1 (Hong, et al., 1996; Voegel, et al., 1996), RAC3 (Li, et al., 
1997), AIB1 (Anzick, et al., 1997), ACTR (Chen, et al., 1997), and P/CIP 67 
(Torchia, et al., 1997).  Proteins within the SRC-1 family appear to interact 
exclusively with transcription factors of the nuclear receptor superfamily 
(Torchia, et al., 1997).  In contrast, CBP and p300, which appear to be 
functionally homologous proteins, have been shown to interact with a 
plethora of signaling molecules and have been termed "integrator" proteins 
(Kamei, et al., 1996 and reviewed in Janknecht and Hunter, 1996a).  In fact, 
several signaling pathways appear to converge at the level of CBP and/or 
p300 which may be the molecular basis of reciprocal antagonism between 
AP-1 and: (1) retinoid receptors (Kamei, et al., 1996), (2) signal transducers 
and activators of transcription (STATs, Bhattacharya, et al., 1996; Horvai, et 
al., 1997), and (3) p53 (Avantaggiati, et al., 1997; Lill, et al., 1997). A third 
group of nuclear receptor coactivators that neither exhibit homology to each 
other nor to other classes of coactivators includes RIP140 (Cavailles, et al., 
1995), ARA70 (Yeh and Chang, 1996), SUG-1/TRIP1 (Lee, et al., 1995a; 
Vom Baur, et al., 1996) and TIF1 (Le Douarin, et al., 1995).  While the 
diversity of nuclear receptor coactivators most likely contributes to the 
complexity of receptor-mediated signaling, the precise role of individual 
coactivators and possible synergies or antagonistic interactions between 
coactivators remains to be elucidated. 
We have previously demonstrated that peroxisome proliferating 
agents such as WY-14,643 bind directly to and induce conformational 
change within the PPARa ligand binding domain (LBD, Dowell, et al., 1997). 
We and others have hypothesized that this ligand-induced conformational 
change promotes interaction of the receptors with transcriptional coactivators 
(Allan, et al., 1992a; Allan, et al., 1992b; Dowell, et al., 1997; Leid, 1994). 
Toward the goal of identifying PPARa coactivators, we have used a yeast 
two-hybrid system to isolate several proteins that interact with ligand­68 
activated mouse PPARa (mPPARa). One of the mPPARa-interacting proteins 
isolated in this screen was SRC-1, which has previously been demonstrated 
to interact with PPARy (DiRenzo, et al., 1997; Zhu, et al., 1996). Another such 
protein isolated in our mPPARa screen was p300 which serves as a 
transcriptional coactivator for many other transcription factors, including 
nuclear receptors (Chakravarti, et al., 1996; Kamei, et al., 1996; Smith, et al., 
1996).  In this report, we focus on the interaction of p300 with mPPARa in 
yeast, in mammalian cells and in vitro, and we demonstrate that the manner 
by which p300 interacts with mPPARa appears to be distinct from that of 
either retinoic acid receptor (RAR) or retinoid X receptor (RXR). 
3.3.  Materials and Methods 
3.3.1.  Plasmids and receptor constructs 
Plasmids encoding the receptors described below were used either 
directly or as templates for PCR to assemble all constructs described herein 
using standard techniques.  All plasmids were kind gifts from the following 
individuals: mouse PPARa (Issemann and Green, 1990) from Drs. S. Green 
and J. D. Tugwood (Zeneca, Macclesfield, United Kingdom); mouse RXRa 
and human RARy (RXRa, Leid, et al., 1992 and RARy, Krust, et al., 1989) from 
Drs. P. Kastner, A. Krust, and P. Chambon (IGBMC, Illkirch, France); human 
p300 (Eckner, et al., 1994) from Dr. D. Livingston (DFCI, Boston, MA); mouse 
CBP (Chrivia, et al., 1993) from Drs. R. Kwok and R. Goodman (OHSU, 
Portland, OR). The integrity of all constructs was verified by restriction digest 
and/or sequence analysis.  Additional information concerning any of the 
constructs described herein can be obtained upon request. 69 
Vectors for the yeast two hybrid screen (pBL1, pBTM116, and pASV; 
Le Douarin, et al., 1995), the yeast reporter strains PL3(a) and L40 (Pierrat, 
et al., 1992 and Le Douarin, et al., 1995, respectively), and the randomly 
primed mouse cDNA library inserted into the VP16 AAD-encoded pASV3 
vector (Le Douarin, et al., 1995) were all kind gifts from Drs R. Losson and P. 
Chambon (IGBMC, Illkirch, France).  All yeast expression vectors encoding 
receptor baits were constructed by PCR amplification of the corresponding 
receptors (mPPARa, hRARy, or mRXRa) with primers containing appropriate 
restriction sites for insertion into the Xhol and BamHl sites of pBLI (estrogen 
receptor (ER) DNA binding domain (DBD) fusion) and pBTM116 (LexA DBD 
fusion).  Receptor bait constructs encoded the following amino acids of the 
indicated receptors: PPARa (91-468 of mPPARa), PPARaa,448 (91-447 of 
mPPARa), PPARa D/E (166-468 of mPPARa), PPARa E (282-468 of 
mPPARa), RXRa (132-467 of mRXRa), and RARy (90-454 of hRARy). 
Identical fragments were subcloned in pTL1 (Leid, et al., 1992) and the 
corresponding proteins were expressed by in vitro transcription/translation 
for use in GST pull-down experiments as previously described (Dowell, et al., 
1997). 
The ER DBD fusion expression vectors, ER DBD and ER 
DBD/mPPARa, were contructed by inserting the EcoRl fragment (including 
initiator methionine and favorable Kozak sequence) of pBL1 and 
pBL1/mPPARa, respectively, into the EcoRl site of pTL1. A mammalian 
expression vector for full-length p300 was generated by inserting the 
Notl/HindlIl fragment of pBSK/p300 (Eckner, et al., 1994) into the Notl/HindlIl 
sites of pTL2.  The region of p300 encoding amino acids 39-221 was 
amplified by PCR with a 5' primer introducing a HindlIl site, favorable Kozak 
sequence, and intiator methionine and a 3' primer introducing a BglIl site and 70 
stop codon.  The PCR product was digested with HindlIl and BglIl and 
inserted into the Hindlll /Bglll site of pTL1 generating p300dn.  The ER 
responsive CAT reporter, 17M-ERE-Globin-CAT, has been described 
previously (Nagpal et al., 1997). 
3.3.2.  Yeast two-hybrid screening 
The S. cerevisiae PL3(a) reporter strain expressing the histidine-
selectable pBL1/mPPARa plasmid was co-transformed with a mouse embryo 
cDNA library fused to the VP16 activation domain (on a leucine-selectable 
plasmid; see Le Douarin, et al., 1995 and references therein for details on 
this two-hybrid system).  Approximately 1 X 106 yeast transformants 
(quantitated on His- Leu- plates) were screened for URA3 reporter activity on 
His- Leu- Ura- plates containing 30 µg /ml 6-azauracil.  Preliminary results 
indicated that the pBL1/mPPARa expressing PL3(a) strain exhibited residual 
URA3 expression sufficient to allow growth on Ura- media (data not shown), 
therefore, inclusion of 6-azauracil (an inhibitor of the URA3 gene product) 
was necessary to restore uracil auxotrophy.  Ligand-independent and 
-dependent screens were conducted in the absence and presence of 100 jiM 
WY-14,643, respectively, in all synthetic media.  Positive clones from both 
screens were isolated and replated on Leu- plates to allow loss of the 
histidine-selectable pBL1/mPPARa plasmid which was verified by replica 
plating on His- Leu- plates. Leu+ Ura- His- Trp- segregants were then mated 
to the S. cerevisiae L40 reporter strain expressing the tryptophan-selectable 
pBTM116/mPPARa plasmid. Diploids from the mating were then selected on 
Leu- Trp- plates and screened for HIS3 reporter activity on Leu- Trp- His-
plates.  Positive clones were individually grown as liquid cultures in Leu-
media to allow loss of the tryptophan-selectable pBTM116/mPPARa plasmid 71 
and verified by plating on Leu- Trio' plates.  Plasmid DNA from positive 
clones was then isolated and the resulting mouse embryo cDNAs were re­
tested for interaction with the PPARa baits, bait DBDs alone, and non-PPAR 
related baits.  All cDNA clones which exhibited a specific interaction with the 
PPARa baits were then sequenced using the standard dideoxynucleotide 
chain termination method. 
3.3.3.  p-Galactosidase assays 
Yeast cultures, derived from single colonies, were grown in selective 
media for 24 hrs. and then diluted into media containing either vehicle or 
appropriate ligands and grown for an additional 3 hrs.  Cells were then 
permeabilized for 30 min. at room temperature in buffer Z (100 mM Na2HPO4, 
40 mM NaH2PO4  ,  pH 7.8, 10 mM M g SO4, 1 mM KCI, 35 mM p­
mercaptoethanol) containing 0.1% v/v sarcosyl.  3- galactosidase (3 -gal) 
assays were initiated by addition of ONPG and reactions were carried out at 
30°C until a visible color change was evident (0.5  6 hrs.).  p-gal activity was 
determined as follows: 
p gal activity = 
A420 X1000 
t xN 
where A420 is derived from the colorimetric 3 -gal assay, t is the time in hrs., 
and N corresponds to cell number. Ligand dependent assays were carried 
out by inclusion  of  ii M 9-cis RA, 100 1.1M  WY-14,643  (final 
concentrations),or identical amounts of vehicle. 
1 
3.3.4.  GST fusion protein production 
The construct encoding GST/mRXRa has been described (Dowell, et 
al., 1997). The construct encoding GST/hRAR7was prepared by insertion of 72 
a BamHI fragmanet encoding full-length hRARy (Krust, et al., 1989) into 
pGEX-2T (Pharmacia). Constructs encoding GST/p300 and GST/CBP fusion 
proteins were generated by PCR amplification of corresponding coding 
regions from pBSK/p300 (Eckner, et al., 1994) and pRc-RSV/CBP (Chrivia, et 
al., 1993) with all forward primers containing a Bglll site and reverse primers 
containing an EcoRI site. PCR products were then digested appropriately 
and inserted into BamHI/EcoRI-digested pGEX-2T. All GST fusion proteins 
were produced and crude bacterial lysates prepared as previously described 
(Dowell, et al., 1997) except the bacteria were grown in 2X-YT instead of LB 
media. 
3.3.5.  Protein-protein interaction assays 
GST fusion proteins were partially purified using glutathione-
Sepharose 4B (Pharmacia) as per manufacturer's recommendations and 
used directly in protein-protein interaction studies. Assays were initiated by 
addition of 2 [1.1 [35S]methionine-labeled receptor to GST fusion protein-
bound resin equilibrated in binding buffer (10 mM HEPES -NaOH, pH 7.5, 1 
mM EDTA, 1 mM DTT, 100 mM NaCI, 10% glycerol, 0.1% NP-40), and 
incubated with rotation at 4°C for 2 hrs. Unbound proteins were removed by 
3 sequential washes with binding buffer containing vehicle or the appropriate 
ligand. Bound proteins were eluted from the resin by addition of 30 III SDS 
sample buffer and boiled. Samples were then analyzed by SDS-PAGE and 
autoradiography as described previously (Dowell, et al., 1997).  Ligand 
dependent assays were carried out by inclusion of 1 jiM 9-cis RA, 10 iiM WY­
14,643  (final  concentrations),  or an  identical amount of  vehicle. 
Representative gels were lightly stained with Coomassie blue before being 73 
subjected to autoradiography to ensure that equal amounts of GST fusion 
proteins were included in each reaction.  Independent experiments were 
conducted at least three times and representative results are shown. 
Protein-protein interaction assays using P19 embryonal cell nuclear 
extracts were conducted as described above except that GST or GST/p300 
[1-450] was incubated with P19 cell nuclear extracts (see below) instead of 
[35S]methionine-labeled receptor preparations and ligand-dependent 
assays were carried out in binding buffer containing 100 RM WY-14,643. 
Bound proteins were analyzed by immunoblot analysis as described 
previously (Leid, 1994) using a polyclonal antibody that recognizes an 
epitope in the highly conserved carboxy terminal region of PPAR subtypes 
(Affinity Bioreagents, Cat.#PA3-820). 
3.3.6.  Electrophoretic mobility shift assays 
Electrophoretic mobility shift assays were conducted essentially as 
described previously (Dowell, et al., 1997) except receptor-DNA complexes 
were incubated with -500 ng of purfied GST or GST/p300 [39-117] for an 
additional 10 min. The acyl-CoA oxidase peroxisome proliferator response 
element (PPRE) probe has been described previously (Tugwood, et al., 
1992). Ligand dependent assays were carried out by inclusion of 1  j.t.M 9-cis 
RA, 10 jiM WY-14,643 or vehicle. 
3.3.7.  Cell culture and nuclear extract preparation 
Human embroynic kidney (HEK) 293 cells (ATCC CRL 1573) were 
cultured in Minimum Essential Medium (MEM) with Earle's salts (Sigma) 
supplemented with 10% horse serum (GibcoBRL) and 4 mM glutamine (both 74 
from Life Technologies, Inc.).  Cells were grown to 50-60% confluence and 
transiently transfected using the calcium phosphate method. Each 100 mm 
plate was cotransfected with 0.5 lig pf expression vector encoding the ER 
DBD or ER DBD /PPARa fusion protein, 2 lig of the 17M-ERE-Globin-CAT 
reporter construct, variable amounts of either wild-type p300 or p300dn and 
2 pig of pCH110 (Pharmacia) encoding J3- galactosidase which was used to 
normalize for transfection efficiency.  Transfected cells were incubated with 
WY-14,643 (10 gM) or vehicle for 24 hours. n -gal and CAT activities were 
quantified  spectrophotometrically  and  by  thin  layer 
chromatography/scintillation  counting,  repectively,  using  standard 
techniques. 
P19 embryonal carcinoma cells (Rossant and Mc Burney, 1982) were 
cultured on 100 mm plates in MEM supplemented with 10% fetal bovine 
serum (Hyclone).  Nuclear extracts were prepared from cells  at 
approximately 80% confluence essentially as described in (Andrews and 
Faller, 1991).  Briefly, cells were washed once with PBS, scraped from 
plates, and resuspended in cold buffer A (10 mM HEPES-KOH, pH 7.9, 1.5 
mM MgCl2, 10 mM KCI, 0.5 mM dithiothreitol, 0.2 mM PMSF). Cells were 
allowed to swell on ice for 10 minutes, vortexed, and centrifuged to pellet 
nuclei. The pellet was resuspended in Buffer C (20 mM HEPES-KOH, pH 
7.9, 25% glycerol, 420 mM NaCI, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
dithiothreitol, 0.2 mM PMSF) and incubated on ice for 20 minutes.  Cellular 
debris was pelleted by centrifugation and the supernatant containing the 
crude nuclear extract was frozen at -80°C until used. 75 
3.3.8.  Chemicals and reagents
 
WY-14,643 was purchased from Chemsyn (Lenexa, KS) and all 
radioisotopes were purchased from NEN DuPont. 
3.4.  Results 
3.4.1.  Introduction 
Using a previously described yeast two hybrid system (Le Douarin, et 
al., 1995), two mPPARa-interacting clones were isolated, sequenced and 
determined to encode fragments of the nuclear receptor coactivators, p300 
(Kamei, et al., 1996) and SRC-1 (Onate, et al., 1995; see Fig. 3.1A and B). 
Both isolated fragments contain at least one copy of the recently identified 
LXXLL motif which has been shown to mediate interactions between co­
activators and nuclear receptors (see Figs. 3.1A and B; Torchia, et al., 1997). 
Although an interaction between PPARy and SRC-1 has been reported 
previously (DiRenzo, et al., 1997; Zhu, et al., 1996), to our knowledge, this is 
the first report of a p300-PPARa interaction, and for this reason, we chose to 
conduct further experiments with PPARa and p300. 
3.4.2.  p300 amino acids 39-221 interact with PPARa but not 
RXRa or RARy 
Interestingly, the isolated fragment of p300 (encoding amino acids 39­
221, Fig. 3.1A) that exhibited a strong interaction with the PPARa bait did not 
interact detectably with either RXRa or RARy baits in the absence or 
presence of 9-cis retinoic acid (9-cis-RA) in yeast (Fig. 3.2A). However, the 
isolated fragment of SRC-1 (encoding amino acids 579-931, Fig. 3.1B), 
which interacted with PPARa in a ligand-enhanced manner, did exhibit a 76 
A  p300 
1 MAENVVEPGPPSAKRLKLSSPALSA
 
26  SASDGTDFGSLFDLEHDLPDELINS 
51 TELGLTNGGDSSOLOTSLGIVODAA 
76 SKHKOILSELIARSGSSPNLNMGVGGP 
101 GQAMASQACQNSPGLSLINSMVKSP 
126  MACTGLTSPNMGIGSSGPNOGPTOS 
151 PAGMINSP'VNOPAMGMNTGMNAGMN 
176 PGMLAAGNGQGIMPNQVMNGSIGAG 
201  RGRPNMQYPNAGMGNAGSLLTEPLQ 
226  QGSPQMGGQPGLRGPQPLKMGMMNN 
251 PSPYGSPYTQNSGQQIGASGLGLQI 
276 QTKTVLPNNLSPFAMDKKAVPG... 
B  SRC-1 
551  ...GFSAGSPVLRQMSSQNSPSRLS
 
576  MQPAKAESKDSKEIASILNEMIQSD 
601 NSDNSANEGKPLDSGLLHNNDRLSE 
626 GDSKYSOTSHNLVOLLITTTAEOOLR 
651  HADIDTSCKDVLSCTGTSSSASSNP 
676 SGGTCPSSHSSLTERHKIILHRL4QE 
701  GSPSDITTLSVEPEKKDSVPASTAV 
726 SVSGQSQGSASIKLELDAAKKKESK 
751 DHOWJRYLIADKDEKDLRSTPNLCLD 
776 DVKVKVEKKEQMDPCNTNPTPMTKP 
801  APEEVKLESOSOFTADLDQFDOLLP 
826  TLEKAAQLPSLCETDRMDGAVTGVS 
851  IKAEVLPASLOPTTARAAPRLSRLP 
876  ELELEAIDNQFGQPGAGDQIPWANN 
901  TLTTINQNKPEDQCISSQLDELI4CP 
926 PTTVEGRNDEKALLEQLVSFLSGKD
 
951 ETELAELDRALGIDKLVQGGGL...
 
Fig. 3.1.  Isolation of p300 and SRC-1 as mPPARa-interacting 
proteins. A, p300 and 8, SRC-1 fragments isolated in a mPPARa yeast 
two-hyrbid screen. The coactivator encoded fragments isolated in the screen 
are indicated by bold, underlined text (amino acids Leu39-Thr221 and Ala579­
A rg 931 of p300 (Arany et al., 1994) and SRC-1 (Kamei et al., 1996), 
respectively) and the recently identified receptor-interacting motifs, LXXLL 
(Torchia et al., 1997; Heery et al., 1997; Thenot et al., 1997), are stipled. 77 
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Fig. 3.2.  Interactions between coactivator fragments and PPARa, 
RARy, and RXRa. A, Interactions between coactivator fragments and 
nuclear receptors in yeast.  LexA/receptor fusions were coexpressed with 
VP16AAD/coactivator fragment fusions and examined for the ability to 
activate an integrated LexA-responsive lacZ reporter in the yeast strain L40. 
Ligand-dependent interactions were examined in the presence or absence 
of 100 µM WY-14,643, 1 1AM 9-cis RA, or an equal amount of vehicle where 
indicated.  At least three independent transformants were assayed for each 
experiment and the results shown represent the mean ± S.E.M. of three 
independent experiments.  No reporter activity was detected when 
VP16AAD/coactivator fragment fusions were coexpressed with either LexA 
alone or LexA fused to an unrelated protein (data not shown).  B, In vitro 
protein-protein interactions between coactivator fragments and nuclear 
receptors. A GST/p300 fusion protein corresponding to the isolated p300 
fragment (GST/p300-(39-221)) was bound to glutathione Sepharose and 
used as an afffinity matrix to examine interactions with in vitro translated 
[35S]methionine-labeled PPARa, RARy, and RXRa in the absence and 
presence of ligand (10 µM WY-14,643 or 1µM 9-cis RA as indicated).  All 
receptors preparations expressed in yeast or translated in vitro were 
truncated in the amino terminal (AAB) region. 78 
strong  ligand-dependent  interaction  with  both RXRa and RARy 
demonstrating that all three baits are expressed in a functional form in this 
yeast strain (Fig. 3.2A).  Compared with the strong 9-cis RA-dependent 
interaction observed between both the RXRa and RARy baits and the SRC-1 
fragment, stimulation of the interaction between the PPARa bait and both 
coactivator fragments by the PPAR ligand, WY-14,643, was modest yet 
significant (p < 0.05, Fig. 3.2A). A strong interaction between PPARa and 
both SRC-1 and p300 was observed in the absence of WY-14,643 (Fig. 3.2A) 
consistent with observations previously reported for the interaction of PPARy 
and SRC-1 (Zhu, et al., 1996).  This may be due, at least in part, to the 
presence of high levels of endogenous PPAR activators in yeast, such as 
fatty acids and/or derivatives of fatty acids. 
To confirm the observed interactions in vitro, p300-(39-221) was 
expressed in bacteria as a GST fusion protein and immobilized on 
glutathione-Sepharose beads. The immobilized protein was then used as 
an affinity matrix to examine interactions with in vitro translated PPARa, 
RXRa, and RARy. As observed in the yeast two hybrid system, PPARa 
exhibited a strong specific interaction with the GST/p300-(39-221) fusion. 
However, the in vitro interaction was strictly dependent on the presence of 
WY-14,643 (Fig. 3.2B, lanes 2 and 3).  This ligand-dependent interaction 
was in contrast to that of the ligand-independent interaction observed 
between GST/RXRa and PPARa (see below, Fig. 3.4A, lanes 4 and 5 ). 
RARy and RXRa did not interact with the GST/p300-(39-221) fusion protein in 
the absence or presence of 9-cis RA (Fig. 3.2B, lanes 5, 6, 8, and 9, 
respectively) in agreement with the yeast two-hybrid data (Fig. 3.2A). The 
integrity of the in vitro translated RXRa and RARy proteins was confirmed by 
interaction with GST/RARy and GST/RXRa fusion proteins, respectively (see 79 
below, lanes 4 and 5 of Fig. 3.4, B and C, respectively), and DNA binding 
activity (data not shown).  Therefore, amino acids 39-221 of p300, which 
interacted strongly with PPARa, were not sufficient for interaction with the 
retinoid receptors, RXRa and RARy, as detected in our assays in yeast and in 
vitro.  It should be noted, however, that other groups have reported both 
CBP-RXRa (Chakravarti, et al., 1996), CBP-RARa, and p300-RARa (Kamei, et 
al., 1996) interactions using yeast two-hybrid systems. The region of p300 
examined in our studies is partially overlapping, but not identical to, those (or 
homologous regions of CBP) used by Kamei and co-workers (Kamei, et al., 
1996) and Chakravarti and collaborators (Chakravarti, et al., 1996). 
3.4.3.  Residues within the carboxyl-terminal and hinge
regions of PPARa are required for interaction with p300 
To determine which regions of PPARa are required for interaction with 
p300-(39-221) in yeast, we constructed three additional PPARa baits as 
follows: 1) PPARaA448-(91-447) which is missing 21 carboxyl-terminal 
amino acids (in addition to the 90 amino-terminal residues which are also 
truncated in PPARa; see "Materials and Methods"), 2) PPARa DIE-(166-468) 
encompassing the hinge and ligand binding domain (LBD), and 3) PPARa E­
(281-468) encompassing the LBD alone as defined by lssemann and Green 
(1990). When these baits were examined in yeast, we were unable to detect 
an interaction between p300-(39-221) and either PPARaA448 or PPARa E in 
the absence or presence of WY-14,643 (Fig. 3.3A).  In contrast, a strong 
interaction was detected with both SRC-1 and p300 using the PPARa D/E 
bait and these interactions were modestly but significantly enhanced by WY­
14,643 (Fig. 3.3A), as observed for PPARa (Fig. 3.2A). 80 
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Fig. 3.3.  Interactions  between  p300-(39-221)  and truncation 
mutants of PPARa. A, Interactions between p300 coactivator fragment and 
mutant PPARs in yeast.  The 21 amino acid carboxy terminal truncation 
mutant, PPARco,448, and the amino terminal truncation mutants, PPARa D/E 
and PPARa E, encompassing the hinge/LBD and LBD of PPARa, 
respectively, were examined as LexA DBD/receptor baits as described in Fig. 
2A. 8, In vitro protein-protein interactions between p300-(39-221) and mutant 
PPARs. Assays were conducted as described in the legend of Fig. 2B. 81 
Protein-protein interaction assays, as described above, were also 
conducted with in vitro translated PPARaA448, PPARa D/E, and PPARa E.  In 
agreement with our yeast two-hybrid data, no interaction was detected 
between GST/p300-(39-221) and either PPARaA448 or PPARa E (Fig. 3.3B, 
lanes 2, 3, 8, and 9).  In contrast to PPARaA448 and PPARa E, a strong 
interaction was detected between GST/p300-(39-221) and PPARa D/E (Fig. 
3.3B, lanes 5 and 6).  As observed with PPARa, the in vitro  interaction 
between p300 (39-221) and PPARa D/E was more strongly ligand-enhanced 
than that in yeast. Our yeast two-hybrid and in vitro data suggest that the 
carboxyl-terminal 21 amino acids as well as residues within the hinge of 
PPARa are required for interaction with p300-(39-221). 
3.4.4. Amino acids 39-117 of p300 are sufficient for
interaction with PPARa 
To define further the region of p300 required for interaction with 
PPARa, several fragments of p300 were expressed as GST fusions proteins 
and examined for interaction with PPARa as well as RXRa and RARy as 
described above. PPARa, RARy, and RXRa all exhibited specific interactions 
with GST/p300 amino acids 1-450 (GST/p300-(1-450)), but the interaction 
with RXRa in the presence of 9-cis RA was relatively weak (Fig. 3.4C lanes 6 
and 7) and was more readily apparent upon overexposure of the dried gel 
(data not shown). In contrast, RXRa exibited a strong ligand-independent 
interaction with GST/RARy (Fig. 3.4C, lanes 4 and 5) demonstrating the 
integrity of this preparation of RXRa. RARy consistently exhibited a ligand­
enhanced interaction with GST-p300-(1-450) (Fig 3.4B,lanes 6 and 7) in 
addition to a strong ligand-independent interaction with GST/RXRa (Fig. 
3.4B, lanes 4 and 5).  Surprisingly, the GST/p300-(1-450)-PPARa interaction 82 
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Fig. 3.4.  Interactions between regions of p300 and PPARa, RARy,
and RXRa. A, In vitro protein-protein interactions between coactivator 
fragments and PPARa. Fragments of p300 ((1-450), (1-117), and (39-117)) 
were expressed as GST fusion proteins and examined for interactions with in 
vitro translated [35S]methionine-labeled PPARa as described in Fig. 2B. 
Note that the integrity of the in vitro translated PPARa was demonstrated by 
interaction with GST/mRXRa. B, In vitro protein-protein interactions between 
coactivator fragments and RARy. Assays were carried out as described 
above (Fig. 4A). C, In vitro protein-protein interactions between coactivator 
fragments and RXRa. Assays were carried out as described above (Fig. 4A) 
except the integrity of the in vitro translated RXRa was demonstrated by 
interaction with GST/hRARy. 83 
was unaffected by addition of WY-14,643 (Fig. 3.4A, lanes 6 and 7).  In 
contrast, PPARa exhibited a ligand-dependent interaction with GST/p300-(1­
117) and -(39-117) (Fig. 3.4A, lanes 8-10 and 11) as observed for GST/p300­
(39-221) (see above, Fig. 3.28). The molecular basis for this variable degree 
of ligand dependence when examining PPARa interactions with different 
regions of p300 and vice versa (see below)  is  presently unknown. 
Nonetheless, a minimal PPARa interaction domain encompassing p300 
amino acids 39-117 was defined.  In addition, results from experiments 
conducted with GST/CBP-(1-115) demonstrate that PPARa, but neither RARy 
nor RXRa, interact with CBP amino acids 1-115 in a ligand-dependent 
manner in vitro (data not shown).  It should be noted that although Kamei and 
co-workers (Kamei, et al., 1996) demonstrated an interaction between RARa 
and p300-(1-117) in a yeast two-hybird assay (Kamei, et al., 1996), we did 
not observe an interaction between RARy and p300-(1-117) in vitro  (Fig. 
3.48, lanes 8 and 9 ).  However, we did observe ligand-enhanced, in vitro 
interactions between both RARy and RXRa and GST/p300-(1-450) (lanes 6 
and 7 of Figs. 3.4B and C, respectively) in agreement with the observations 
of Kamei and collaborators (Kamei, et al., 1996). Discrepancies between our 
results and those published previously may simply reflect the different 
subtypes of RAR used (a versus y) and/or differential sensitivities when 
comparing the two assays.  In fact, other groups have also noted conflicting 
results when comparing in vitro interactions with those in yeast (Lee, et al., 
1995a). 
We next conducted additional protein-protein interaction experiments 
to define regions of both PPARa and p300 that are required for efficient 
interaction.  PPARaA448, PPARa D/E, and PPARa E all exhibited a ligand­
independent interaction with GST/p300-(1-450) (lanes 6 and 7 of Fig. 3.5A, B 84 
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Fig. 3.5. Interactions between regions of p300 and truncation
mutants of PPARoc. A, In vitro protein-protein  interactions between 
coactivator fragments and PPARaA448.  Assays were conducted as 
described in  Fig. 4A. 8, In vitro protein-protein  interactions between 
coactivator fragments and PPARa D/E. Assays were carried out as described 
above (Fig. 5A). C, In vitro protein-protein interactions between coactivator 
fragments and PPARa E. Assays were carried out as described above (Fig. 
5A). 85 
and C, respectively).  PPARa D/E, containing both the hinge and ligand 
binding domain, exhibited an interaction profile similar to that of PPARa 
(compare Figs. 3.4A with 58) except that the interaction of PPARa D/E with 
GST/RXRa was enhanced by WY-14,643 (Fig. 3.58, lanes 4 and 5).  Neither 
PPARa6,448 nor PPARa E was capable of interacting with smaller fragments 
of p300 fused to GST (GST/p300-(1-117) and -(39-117)) in the absence or 
presence of WY-14,643 (lanes 8-11 of Fig. 3.5, A and C, respectively). 
Although a strong ligand-independent interaction between PPAR00,448 and 
GST/mRXRa was observed (Fig. 3.5A, lanes 4 and 5), only a weak 
interaction between PPARa E and GST/mRXRa was observed which was 
more apparent upon overexposure of the dried gel (data not shown). As 
demonstrated previously, PPARaA448 responded to WY-14,643 in a 
differential proteolytic sensitivity assay demonstrating that this mutant 
receptor is capable of binding ligand (Dowell, et al., 1997).  Our in vitro 
results further support the conclusion that the carboxyl-terminal 21 PPARa 
residues are required for interaction with the minimal PPARa-interaction 
domain of p300-(39-117).  In addition, residues contained within the hinge of 
PPARa (166-281) are also required for the interaction of the receptor with 
p300-(39-117).  In contrast, it appears that only PPARa amino acids 281-447 
are required for the ligand independent interaction observed with p300 -(1­
450) as all PPARa mutants examined were capable of interacting with this 
fragment regardless of the presence of ligand. 
3.4.5. p300 interacts with a PPARa/RXRa heterodimer bound 
to DNA 
We next conducted electrophoretic mobility shift assays to determine if 
PPARa/RXRa heterodimers could interact with a p300 fragment while bound 86 
to DNA.  Addition of GST/p300-(39-117), but not GST alone, to a 
RXRaPPARaPPRE complex resulted in a pronounced mobility shift 
indicating the formation of a oligomeric RXRaPPARaGST/p300-(39­
117)PPRE complex (Fig. 3.6, compare lanes 1 and 2 with lanes 5 and 6). 
The presumed oligomeric complex formation was only modestly stimulated 
by ligand,  in contrast to results obtained from in vitro protein-protein 
interaction assays with this particular fragment of p300 (Fig. 3.4A). No 
binding of RXRa homodimers to the PPRE was observed excluding the 
possibility that the GST/p300 protein was interacting with a PPRE-bound 
RXR homodimer (data not shown).  In addition, no interaction between a 
canonical DR1-bound RXRa homodimeric complex and GST/p300-(39-117) 
was observed in the absence or presence of 9-cis RA (data not shown). 
RXRa/RARy heterodimers similarly did not exhibit interactions with the 
GST/p300-(39-117) protein when bound to either DR1 or DR5 response 
elements (data not shown). 
3.4.6.  p300 enhances the transcriptional activation properties 
of PPARa 
To examine the effect of p300 on the transcriptional activation 
properties of PPARa, we utilized a fusion protein encoding the DBD of ER 
fused to amino acids 91-468 of PPARa (ER DBD/PPARa) in conjunction with 
an ER-responsive CAT reporter.  Coexpression of p300 in HEK 293 cells 
significanity enhanced the ability of the ER DBD/PPARa, but not that of the 
empty ER DBD expression vector, to activate transcription of CAT both in the 
presence and absence of WY-14,643 (Fig. 3.7). ER DBD/PPARa activated 
transcription strongly in the absence of exogenous activator, and this activity 
was slightly stimulated by 10 j.tM WY-14,643 (Fig. 3.7, lanes 1 and 2). A 87 
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Fig. 3.6. p300-(39-221)PPARaRXRa oligomeric complex formation
on a PPRE. The filled arrow indicates position  of PPARa/RXRa
heterodimeric complexes and open  arrow  indicates  position  of 
p300PPARcxRXRa oligomeric complexes. No binding of GST or GST /p300­
(39 -221) in the absence or presence of unprogrammed lysate and/or ligand 
was observed (data not shown). 88 
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Fig.  3.7.  Effect  of p300 and p300dn on the transcriptional
activation properties of ER DBD/PPARa. in HEK 293 cells.  Cells 
were cotransfected with the indicated expression vectors and treated with 
DMSO or 10µM WY-14,643 for 24 hrs. CAT activity was determined by thin 
layer chromatography using [14C]chloramphenicol and visualized by 
autoradiography.  Radioactive species from three independent experiments 
were excised and quantified by liquid scintillation counting.  Bars represent 
the mean ± S.E.M. (n = 3) values of the percent [14C]chloramphenicol 
converted to acetylated forms for a given treatment. Note that PPARAAB is 
ER DBD/PPARa. 89 
dominant negative form of p300, p300dn (corresponding to amino acids 39­
221), was used to address the role of endogenous p300 or that of other 
transcriptonal coactivators, in the constitutive activity of ER DBD/PPARa 
observed in HEK 293 cells. As observed with assays in yeast, endogenous 
PPAR activators may be responsible for the ostensibly ligand-independent 
activity of ER-DBD/PPARa. Coexpression of p300dn with ER DBD/PPARa 
resulted in a striking inhibition of both ligand-independent and -dependent 
transcriptional activation properties of the receptor (Fig. 3.7, lanes 7-10 ). 
When consideredogether, our results suggest that p300 functions as a bona 
fide PPARa coactivator by enhancing the transcriptional activation 
capabilities of the receptor.  Conversely, p300dn appears to function as a 
potent dominant negative inhibitor of PPARa-mediated activation, suggesting 
that endogenous p300 or possibly other transcriptional coacti tvators mediate 
the constitutive activity of PPARa in HEK 293 cells. 
3.4.7.  p300 interacts with endogenous PPAR from mammalian
cells 
Finally, experiments were carried out to determine if a fragment of 
p300 was capable of interacting with endogenous PPAR expressed in a 
mammalian cell line. GST alone, GST/mRXRa, or GST/p300-(1-450) was 
bound to glutathione-Sepharose and incubated with nuclear extracts from 
P19 mouse embryonal carcinoma cells in the absence or presence of WY­
14,643.  Bound proteins were then eluted, electrophoresed, transferred to 
nitrocellulose, and subjected to immunoblot analysis using antisera that 
recognizes all PPAR subtypes.  A ligand-independent interaction was 
detected between endogenous PPAR and both GST/mRXRa and GST /p300­
(1 -450) (Fig. 3.8, lanes 5-8), in agreement with data discussed above (see 90 
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Fig. 3.8.  In vivo interaction between p300 and endogenous PPAR. 
GST/p300-(1-450) was bound to glutathione Sepharose and used as an 
affinity matrix to examine interactions with endogenous PPAR(s) from 
mammalian cell lysates.  Experiments were conducted essentially as 
described in Fig. 4A except cell lysates from P19 cells were incubated with 
GST or GST/p300-(1-450) in the absence and presence of 100 1AM WY­
14,643.  Bound proteins were then eluted and subjected to immunoblot 
analysis with anti-sera that recognizes an epitope common to all known 
PPAR subtypes (see Materials and Methods).  The arrows indicate the 
positions two proteins that are recognized this antibody. Each protein is in 
the range of 51-55 kDa which is consistent with the calculated mass of 
PPARs. Immunoblot analysis of material retained on the GST/p300-(1-450) 
column using preimmune sera (PI) did not reveal the immune complexes 
indicated above by the filled arrows (data not shown). 91 
Fig. 4A), whereas no interaction was observed with GST alone (Fig. 
3.8,lanes 3 and 4). The immunoreactive signals we observed were specific 
for PPAR as preimmune sera was ineffective (Fig 3.8. lane 1 and data not 
shown).  Two P19 cell nuclear proteins that migrated with predicted 
molecular mass consistent with that of PPAR subtypes (-51-55 kDa) were 
specifically retained by the GST/p300-(1-450) (see arrows in Fig. 3.8). These 
proteins could represent different subtypes of PPAR or degradation products 
thereof.  Alternatively, these proteins may represent unphosphorylated and 
phosphorylated forms of a single or multiple PPARs as recent reports have 
shown that both PPAR-a and -y subtypes are phosphorylated (Adams, et al., 
1997; Hu, et al., 1996; Thenot, et al., 1997).  Additional studies will be 
required to address these questions. Nonetheless, our results suggest that 
native PPAR expressed in mammalian cells is capable of interaction with 
p300. 
3.5.  Discussion 
Results described herein extend the group of p300/CBP-interacting 
proteins to include the nuclear receptor PPARa. We have shown that PPARa 
residues within the carboxyl-terminal region of the receptor (amino acids 
448-468) are required for ligand-dependent interactions with the minimal 
PPARa interaction domain of p300 (amino acids 39-117).  Based on the 
crystal structures of RARy (Wurtz, et al., 1996) and RXRa (Bourguet, et al., 
1995; Renaud, et al., 1995) and the predicted structural similarities between 
PPAR, RAR, and RXR (Wurtz, et al., 1996 and data not shown), PPARa amino 
acids 448-468 correspond to a portion of putative helix 11 and all of putative 
helix 12 (see Wurtz, et al., 1996 and Dowell, et al., 1997).  Helix 12, which 
contains a conserved transcriptional activation function (AF-2), appears to 92 
fold back upon the core receptor molecule in the ligand-bound state and may 
contribute part of a larger ligand-dependent interaction surface for receptor-
interacting proteins such as coactivators. Indeed, point mutations within the 
AF-2 of other nuclear receptors have been shown to abolish or inhibit 
interactions with coactivators (Chakravarti, et al., 1996; Kamei, et al., 1996; 
Le Douarin, et al., 1995; Voegel, et al., 1996; Vom Baur, et al., 1996).  In this 
model, deletion of helix 12 or mutation of key residues within helix 12 would 
effectively destroy part or all of the ligand-dependent coactivator interaction 
surface. The PPARa mutant, PPARaA448, which is missing putative helix 12 
but still binds WY-14,643 (Dowell, et al., 1997), does not interact with the 
minimal PPARa interaction domain of p300 (39-117) in contrast to PPARa 
which interacts with this region of p300 in a strictly ligand-dependent 
manner. Our results are in agreement with the model proposed above, and 
recent studies have demonstrated that deletion of 11 amino acids from the 
carboxyl-terminal region of PPARy abolishes transcriptional activation 
although the effects on coactivator interactions were not examined (Zamir, et 
al., 1997). This region is well conserved across PPAR subtypes, and it will 
be of interest in future studies to determine if loss of transcriptional activation 
correlates with loss of coactivator interactions.  Studies with other nuclear 
receptors have shown that the AF-2, while being required, is not sufficient for 
receptor-coactivator interactions (Thenot, et al., 1997) suggesting that other 
regions within the receptor may also be involved.  Although we did not 
directly examine if the 21 carboxyl-terminal amino acids of PPARa alone 
were sufficient for interaction with p300, we were unable to demonstrate an 
interaction between a larger PPARa fragment containing this region (PPARa 
E) and all p300 fragments examined except 1-450, and the latter interaction 
was entirely ligand-independent.  The ligand-dependent nature of the 93 
interaction with p300 fragments 39-221, 1-117, and 39-117 was restored 
when the hinge region was added to the LBD (PPARa D/E) suggesting that 
the extreme carboxyl-terminal region of the receptor as well as amino acids 
that comprise the hinge region are required for ligand-dependent interaction 
with the smaller p300 fragments. The region of mPPARa referred to herein 
as the hinge, amino acids 166-282, is predicted to include a helices 1-4 
based on structural similarity with the retinoid receptors (Wurtz, et al., 1996 
and data not shown). Hsu and co-workers (1995) have demonstrated that 
point mutation of Glu282--Gly attenuated the constitutive transcriptional 
activation properties of mPPARa highlighting the importance of this region in 
mPPARa signaling.  However, mutation of Glu282 likely affected the ligand 
binding properties of mPPARa rather than its ability to interact with 
coactivators because the maximal extent of inducible transcriptional 
activation was unchanged (Hsu, et al.,  1995).  Similarly, the observed 
differential ability of mPPARa E and mPPARa D/E to interact with p300 
fragments may be related to differing affinities of these two receptor regions 
for WY-14,643. The results of these studies using mPPARa E and mPPARa 
DE did not allow discrimination between an inability to bind ligand and a 
defect in receptor/p300 interactions. 
We have demonstrated that 79 amino acids of p300 (39-117) and 115 
amino acids of CBP (1-115) are sufficient for interaction with PPARa in vitro. 
One copy of the recently identified LXXLL nuclear receptor interaction motif 
(Heery, et al., 1997; Thenot, et al., 1997; Torchia, et al., 1997) is contained 
within these regions (amino acids 81-85 of p300 and 69-73 of CBP; see Fig. 
3.1A and data not shown), and our studies demonstrate that this single motif 
is clearly sufficient for interaction with mPPARa, but not RARy or mRXRa, in 
vitro. A second LXXLL motif is present outside this region within amino acids 94 
344-348 of p300 and 357-361 of CBP (Heery, et al., 1997), and it  is 
conceivable that both motifs are required for interaction with the retinoid 
receptors examined in this study.  However, Kamei and co-workers (1996) 
previously demonstrated that p300-(1-117), which contains the identical 
LXXLL motif present in p300-(39-221), interacts with RARa when examined 
in the yeast two-hybrid system. The basis for this discrepancy is presently 
unknown but may involve a lack of sufficient sensitivity in our assays which 
would have permitted detection of  weak interactions.  Nonetheless, our 
observations clearly demonstrate that p300 amino acids 39-221 interact 
robustly with PPARa, but not detectably with RARy or RXRa, both in yeast and 
in vitro. We hypothesize that these differential interactions are a result of 
different affinities of each receptor with this particular coactivator/integrator 
protein and are not indicative of an exclusive PPARa interaction.  Indeed, 
other coactivators appear to interace preferentially, althought not exclusively, 
and/or augment the transcriptional activation properties of particular nuclear 
receptors (Chen, et al., 1997).  These observations may be particularly 
relevant to the functioning of receptor-coactivator complexes in vivo where 
the concentrations of receptors, coactivators, or both may be limiting and in 
competition with each other.  In this manner, an additional layer of regulation 
is afforded by coactivators in establishing a finely tuned signaling system. 
The nuclear proteins p300 and CBP are increasingly identified as 
common components of a variety of signaling pathways (reviewed in Arany, 
et al., 1996; Avantaggiati, et al., 1997; Bhattacharya, et al., 1996; Horvai, et 
al., 1997; Janknecht and Hunter, 1996a; Lill, et al., 1997; Puri, et al., 1997). 
The central role of CBP in vivo is underscored by the identification of three 
human diseases that are attributable to mutations in the CBP gene: (1) 
Rubinstein-Taybi syndrome (Petrij,  et  al.,  1995), (2) myelodysplastic 95 
syndrome (Taki, et al., 1997), and (3) acute myeloid leukemia (Borrow, et al., 
1996).  Although tranlocations involving chromosome regions that map 
within the same region as the p300 locus have been linked to a leukemia 
similar to that of acute myeloid leukemia (Borrow, et al., 1996), it remains to 
be firmly established if dysfunctional forms of p300 also give rise to human 
maladies.  It will be of critical importance to determine the precise role of 
p300 and/or CBP in PPAR signaling and if other signaling pathways cross­
talk at the level of PPARa coactivators such as p300/CBP and SRC-1. 
Our results demonstrate that p300 is a bona fide coactivator for the 
nuclear receptor PPARa. Recently, two independent groups reported that 
p300 is also capable of interacting directly with and augmenting the 
transcriptional activation properties of the tumor suppressor protein, p53 
(Avantaggiati, et al., 1997; Lill,  et al., 1997).  When these results are 
considered together, it is tempting to speculate that peroxosime proliferator­
induced hepatocarcinogenesis in rodents may be the result of PPARa­
mediated interference with p53 signaling through p300. A mechanistically 
similar phenomenon has been reported for the mutual antagonism between 
nuclear receptors and AP-1 (Kamei, et  al.,  1996).  In  this manner, 
sequestration of the common coactivator, p300, by chronically activated 
PPARa may titrate cellular levels of p300 thereby compromising the tumor 
suppressor activity of p53. Although this scenario may seem plausible, the 
exact molecular mechanisms that may occur and the determinants of 
specificity of such a scenario remain to be discovered. 
3.6.  Abbreviations 
The abbreviations used are: PPAR, peroxisome proliferator-activated 
receptor; mPPARa, murine peroxisome proliferator-activated receptor a; 96 
RXR, retinoid X receptor; RAR, retinoic acid receptor; DR1, direct repeat 
separated by one nucleotide; ER, estrogen receptor; 9-cis-RA, 9-cis-retinoic 
acid; PPRE, peroxisome proliferator-activated response element; DPSA, 
differential protease sensitivity assay; EMSA, electrophoretic mobility shift 
assay; IPTG, isopropyl 13-0-thiogalactopyranoside, LBD, ligand binding 
domain; DBD, DNA binding domain; CAT, chloramphenicol acetyl 
transferase. 
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4.1.  Abstract 
Nuclear receptor corepressor was demonstrated to interact strongly 
with peroxisome proliferator-activated receptor a and the PPARa ligand, WY­
14,643, suppressed this interaction. NCoR and the coactivator, p300, were 
demonstrated to require distinct receptor regions for efficient interaction with 
PPARa. Residues within the amino-terminal portion of the PPARa hinge 
region, that are distinct from those of the conserved CoR box present in 
thyroid hormone and retinoic acids receptors, were essential for interaction 
with NCoR suggesting that PPARa -NCoR interactions are facilitated by a 
novel protein-protein interaction surface.  These observations raise the 
possibility that NCoR may be involved in modulating PPARa- dependent 
transcriptional regulation. 
4.2.  Introduction 
The nuclear receptor superfamily is a large group of structurally 
conserved transcription factors that regulate a wide range of biological 
processes in many organisms both during development and in the mature 
adult (Beato, et al., 1995; Mangelsdorf, et al., 1995).  Members of the 
superfamily function by recognizing specific DNA response elements within 
the regulatory regions of target genes and, often in response to receptor-
specific ligands, modulate expression of these genes at the transcriptional 
level (O'Malley and Tsai, 1992). A large subfamily of orphan receptors, for 
which no ligands have been identified, and receptors for steroid hormones, 
thyroid hormone, peroxisome proliferators, vitamin D3, and the retinoids, all-
trans and 9-cis retinoic acid, are all members of the nuclear receptor 
superfamily. 107 
The mammalian peroxisome proliferator-activated receptor (PPAR) 
family is composed of at least three genetically and pharmacologically 
distinct subtypes, PPARa, -y, and -p/5 (also referred to as NUCI, reviewed in 
Green, 1995; Schoonjans, et al., 1996). The primary physiological roles for 
the -a and -y subtypes of PPAR appear to be regulation of lipid metabolism 
and adipogenesis, respectively, and both subtypes have been implicated in 
modulating inflammatory responses (Bardot, et al., 1993; Devchand, et al., 
1996; Ricote, et al., 1998; Tontonoz, et al., 1994c; Tugwood, et al., 1992; 
Varanasi, et al., 1996).  A physiological role for PPAR(3/6 has not been 
elucidated but this receptor subtype is expressed ubiquitously in the mouse 
suggesting a more general function, while the -a and -y subtypes exhibit 
more restricted expression patterns (Braissant, et al., 1996).  Retinoid X 
receptors (RXRs) serve as obligate heterodimeric partners for all PPAR 
subtypes and the PPAR-RXR heterodimeric complex binds most efficiently to 
degenerate direct repeats of the hexameric nucleotide sequence, AGGTCA, 
separated by one base pair (DR1, Gearing, et al., 1993; lssemann, et al., 
1993; Keller, et al., 1993; Varanasi, et al., 1996). PPAR/RXR heterodimeric 
binding sites have been identified within the regulatory regions of several 
genes that encode proteins involved in lipid metabolism (Bardot, et al., 1993; 
Issemann, et al., 1993; Tugwood, et al., 1992; Varanasi, et al., 1996) and 
adipocyte function (Tontonoz, et al., 1994a; Tontonoz, et al., 1994b). 
PPARa was initially identified in a search for novel superfamily 
members and was shown to be activated by a group of compounds known to 
elicit proliferation of hepatic peroxisomes in rodents (lssemann and Green, 
1990).  Structurally diverse peroxisome proliferators include phthalate ester 
plasticizers  (di(-2-ethylhexyl)-pthalate),  herbicides  (2,4,5­
trichlorophenoxyacetic acid) and several fibric acid anti-hyperlipidemic 108 
agents (WY-14,643, clofibric acid, gemfibrozil; reviewed in Lake, 1995). 
Additional compounds have since been shown to activate PPARa including 
the fatty  acid, arachidonic acid (Gott licher,  et  al.,  1992), and the 
corresponding synthetic analog 5,8,11,14-eicosotetraynoic acid (ETYA, 
(Dreyer, et al., 1992)), the leukotriene D4 antagonist, LY-171883 (Kliewer, et 
al., 1994), and the arachidonic acid derivative and proposed endogenous 
ligand for PPARa, leukotriene B4 (Devchand, et al., 1996). 
In addition to activating expression of target genes upon binding 
cognate ligands, receptors for all-trans retinoic acid (RAR) and thyroid 
hormone (TR) actively repress genes in the absence of ligand (Damm, et al., 
1989; Graupner, et al., 1989).  The related corepressor proteins, nuclear 
receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid 
hormone receptors (SMRT), have been demonstrated to interact with and 
mediate the repression functions of unliganded RAR and TR (Chen and 
Evans, 1995; Horlein, et al., 1995). NCoR and SMRT are associated with a 
multiprotein corepressor complex that minimally contains Sin 3a and the 
histone deacetyltransferase, HDAC1/Rpd3 (Heinzel, et al., 1997; Nagy, et al., 
1997). Ligand binding by RAR and TR promotes dissociation of the receptor­
corepressor complex (Chen and Evans, 1995; Horlein, et al., 1995) and 
subsequent interaction of the receptor with one or more coactivator proteins 
that possess intrinsic histone acetyltransferase (HAT) activity (Kamei, et al., 
1996; Onate, et al., 1995; Torchia, et al., 1997).  Several nuclear receptor-
associated coactivator proteins that exhibit HAT activity have been identified 
including p300/CREB binding protein (CBP, Bannister and Kouzarides, 
1996; Ogryzko, et al., 1996), steroid receptor coactivator-1 (SRC-1, Spencer, 
et al., 1997) and p300/CBP-interacting protein (p/CIP, Torchia, et al., 1997). 
These findings, when considered together with previous observations that 109 
hyperacetylated histones are associated with actively transcribed chromatin 
(reviewed in  Struhl, 1998), offers a molecular explanation for ligand­
dependent transcriptional modulation by nuclear receptors.  Thus, ligand 
binding may serve as a molecular switch between transcriptional repression 
and activation  by promoting exchange of  a  receptor-associated 
deacetyltransferase-containing corepressor complex with that of a histone 
acetyltransferase-containing coactivator complex. 
PPAR-dependent transcriptional activation of many genes is well 
documented and direct ligand-dependent interactions between PPARs and 
the coactivators, p300/CBP (Dowell, et al., 1997a), SRC-1 (Zhu, et al., 1996) 
and PPAR binding protein (PBP, Zhu, et al., 1997), are thought to mediate 
such activation.  In contrast, PPAR-mediated transcriptional repression of 
target genes, as observed for RAR and TR (see above), is relatively 
unexplored or at best controversial. PPARy has been shown to interact in 
solution with the corepressors, NCoR and SMRT, but weakly if at all when 
bound to DNA suggesting that neither of these corepressors mediate putative 
PPAR-dependent gene repression (Zamir, et al., 1997).  In contrast, Lavinsky 
and co-workers demonstrated SMRT-dependent gene repression mediated 
by a phosphorylated form of PPARy (Lavinsky, et al., 1998). Such conflicting 
findings illustrate the need for a more complete mechanistic understanding of 
how and if PPAR-dependent repression occurs. We report here the isolation 
of NCoR from a yeast two hybrid screen using PPARa as a bait. We describe 
results from studies both in yeast and in vitro that were conducted to 
characterize PPARa-NCoR interactions and to examine the influence of 
PPAR ligands upon such interactions. 110 
4.3.  Materials and Methods 
4.3.1.  Plasmids and receptor constructs 
Plasmids encoding the receptors described below were used either 
directly or as templates for PCR to assemble all constructs described herein 
using standard techniques.  All plasmids were kind gifts from the following 
individuals: mouse PPARa (Issemann and Green, 1990) from Drs. S. Green 
and J. D. Tugwood (Zeneca, Macclesfield, United Kingdom); mouse RXRa 
and human RARy (RXRa (Leid, et al., 1992) and RARy (Krust, et al., 1989)) 
from Drs. P. Kastner, A. Krust and P. Chambon (IGBMC, Illkirch, France); 
human p300 (Eckner, et al., 1994) from Dr. D. Livingston (DFCI, Boston, MA). 
The integrity of all constructs was verified by restriction digest and/or 
sequence analysis. 
Vectors for the yeast two hybrid screen (pBL1 and pBTM116, Le 
Douarin, et al., 1995) and the yeast reporter strains PL3(a) and L40 (Refs. 
Pierrat, et al., 1992 and Le Douarin, et al., 1995, respectively) were all kind 
gifts from Drs R. Losson and P. Chambon (IGBMC, Illkirch, France). The 
yeast expression vectors encoding p300 amino acids 39-221 and the 
following amino acids of the indicated receptors have been described 
previously (Dowell, et al., 1997a): PPARa (91-468 of mPPARa), PPARa D/E 
(166-468 of mPPARa), RXRa (132-467 of mRXRa), and RAR7 (90-454 of 
hRAR1). PPARaa,448 (91-447 of mPPARa), PPARa6,425 (amino acids 91­
424 of mPPARa), PPARa E (282-468 of mPPARa) and identical fragments of 
all receptors and mutants thereof listed above were subcloned in pTL1 (Leid, 
et al., 1992) and have been described previously (Dowell, et al., 1997a; 
Dowell, et al., 1997b).  PPARaA288 (amino acids 91-287 of mPPARa), 
PPARaA227 (amino acids 91-226 of mPPARa) and PPARaA202 (amino 111 
acids 91-201 of mPPARa) were constructed by PCR amplification of the 
indicated receptor regions with primers containing appropriate restriction 
sites for insertion into pTL1.  Corresponding proteins of all receptors and 
derivatives thereof were expressed by in vitro transcription/translation for use 
in GST pull-down experiments as previously described (Dowell, et al., 
1997a; Dowell, et al., 1997b).  Note that all constructs encode receptors 
truncated in the amino terminal (zAB). 
GST/p300 has been described previously as GST/p300 (39-221) 
(Dowell, et al., 1997a). GST-NCoR (MD II) and GST-NCoR, encoding GST 
fusions with NCoR amino acids 2218-2381 and 2110-2453, respectively, 
were prepared by PCR amplification with primers containing BamHI and 
EcoRI sites using the original pACT2/NCoR plasmid isolated in the yeast two 
hybrid screen as a template. The resulting fragments were digested and 
subcloned into BamHl /EcoRI digested pGEX2T (Pharmacia).  Additional 
information concerning any of the constructs described herein can be 
obtained upon request. 
4.3.2.  Yeast two-hybrid screening 
The yeast two-hybrid screen was conducted as described in Ref. 
(Dowell, et al., 1997a) except a mouse brain cDNA library inserted into the 
GAL4 activation domain-encoded yeast expression vector, pACT2 (Clontech, 
catalog #ML4008AH), was used in place of the mouse embryo library and 
approximately 2 X 106 yeast transformants were screened.  Plasmid DNA 
from positive clones was then isolated and the resulting cDNAs were re­
tested for interaction with PPAR baits, bait DBDs alone and non-PPAR 
related baits. cDNA clones which exhibited a specific interaction with the 112 
PPAR baits were then sequenced using the standard dideoxynucleotide 
chain termination method. 
4.3.3.	  p-Galactosidase assays 
p-Galactosidase  (p-gal) assays were conducted as described 
previously (Dowell, et al., 1997a). P-gal activity (units) are defined as: 
A420 X1000 p gal activity = 
t x N 
where A420 is derived from the colorimetric 3 -gal assay, t is the time in hrs., 
and N corresponds to cell number (culture volume (0) x A600). 
4.3.4.  Protein-protein interaction assays 
Assays were conducted as described previously (Dowell, et al., 
1997a) and ligand-dependent assays were carried out by inclusion of 1 Al 
9-cis RA, 1 mM clofibrate, 100 IA1 troglitazone, 100 IIM LY-171883, 100 piM 
ETYA, 100 Al WY-14,643 or vehicle in binding buffers except where 
otherwise noted. GST and GST fusion proteins were produced as described 
previously (Dowell, et al., 1997a). 
4.3.5.  Chemicals and reagents 
WY-14,643 and clofibrate were purchased from Chemsyn Science 
Labs (Lenexa, KS) and Sigma (St. Louis, MO), respectively. LY-171883 and 
ETYA were obtained from BIOMOL (Plymouth Meeting, PA).  All 
radioisotopes were purchased from NEN Life Science Products. 113 
4.4.  Results 
4.4.1.  Introduction 
A previously described yeast two-hybrid system (Le Douarin, et al., 
1995) was used to isolate a carboxyl-terminal NCoR fragment as a PPARa­
interacting protein from an oligo dT-primed, mouse brain cDNA library (NCoR 
amino acids 2110-2453, Fig. 4.1).  Previous studies have identified two 
domains, ID I and ID II, that mediate interactions between NCoR and nuclear 
receptors (Horlein, et al., 1995; Seol, et al., 1996).  The NCoR fragment 
isolated in this screen encompasses the last 33 amino acids of ID II and the 
entire ID I (Fig. 4.1). 
PPARa and interaction domains of the coactivators, p300 and SRC-1, 
exhibit strong ligand-independent association when examined with the yeast 
two hybrid system (Dowell, et al., 1997a). When examined in vitro however, 
these interactions are strictly ligand-dependent suggesting that yeast may 
contain unidentified endogenous PPARa ligands (Dowell, et al., 1997a).  It 
was therefore unexpected to isolate NCoR from our two hybrid screen as we 
hypothesized that PPARa existed in a liganded state in yeast that would not 
facilitate receptor interactions with potential corepressor protein fragments as 
observed for other liganded nuclear receptors (Chen and Evans, 1995; 
Horlein, et al., 1995).  In addition, PPAR subtypes do not appear to harbor a 
conserved CoR box, the domain responsible for mediating interactions 
between NCoR and both TR and RAR (DiRenzo, et al., 1997; Horlein, et al., 
1995), despite the demonstration that PPARy can efficiently interact with 
NCoR in solution (Zamir, et al., 1997). Toward the goal of addressing these 
apparent discrepancies, we chose to conduct a more thorough analysis of 
the interaction between PPARa and NCoR. 114 
2010- PDMVKANQAENESTRQYEGPLHHYR 
2035- SQQESPSPQQQPPLPPSSQSEGMGQ 
2060- VP RTHRLITLADHICQIITQDFARN 
2085-QVPSQASTSTFQTSPSALSSTPVRT 
ID II 
2110- KTSSRYSPESOSOTVLHPRPGPRVS 
2135- IPENLVDKS RGSRPGKS PERSH I PSE 
2160- PYEP I S P POGPAVHEKODSMLLLSQ 
2185- RGVDPAEORSDSRS PGS I SYLPSFF 
2210- TKLE STS PMVKSKKOE IFRKLNS SG 
2235- GGDSOMAAAOPGTE I FNLPAVTTSG 
2260- IAVS SRSHSFADPASNLGLEDI I RKA  ID I 
2285- LMGSFDDKVEDHGVVMSHPVGIMPG 
2310- SASTSVVTSSEARRDEGEPSPHAGV 
2335- CKPKL INKSNSRKSKSP I PGOSYLG 
2360- TERPSSVSSVHSEGDYHROTPGWAW 
2385- EDRP S STGSTOFPYNPLTIRML SST 
2410- P PTO IACAP SAI TOAAPHOONRIWE 
2435- RE PAPLL SAOYETL SDSDD* 
Fig. 4.1.  Isolation of NCoR as a PPARa-interacting  protein. 
Carboxyl-terminal NCoR amino acid sequence. The encoded fragment 
isolated in the screen is indicated by bold, underlined text (amino acids 
Lys2110-Asp2453 of NCoR; Horlein, et al., 1995). Previously identified nuclear 
receptor interaction domains, ID  (Asp2239- met2300) and ID II (Arg2062­ I 
ser2142),  are delineated by boxed amino acids (see Seol, et al., 1996). Note 
that amino acids Lys2110-Asp2453 of NCoR are identical to Lys319-Asp662 of the 
originally reported RXR-interacting protein (RIP) 13 isolate (Seol, et al., 
1995). For sake of clarity we have referred to our clone throughout the text 
as NCoR amino acids 2110-2453. 115 
4.4.2.  WY- 14,643 inhibits PPARa interaction with NCoR in a 
dose-dependent manner 
The yeast two-hybrid system was used to compare NCoR interactions 
with PPARa, RARy and RXRa baits.  PPARa interacted specifically and 
robustly with amino acids 2110-2453 of NCoR and the PPARa ligand, WY­
14,643, potently suppressed this interaction while the retinoid receptor 
ligand, 9-cis RA, had no influence (Fig. 4.2A). RARy also interacted with 
NCoR, although with an approximately 5-fold decreased efficiency relative to 
that of PPARa, and 9-cis RA, but not WY-14,643, abolished this interaction 
(Fig. 4.2A).  In contrast, a relatively weak RXRa interaction with NCoR was 
observed and 9-cis RA surprisingly enhanced this interaction (Fig. 4.2A, see 
below). 
To confirm the observed interactions in yeast, in vitro protein-protein 
interaction assays were conducted. A GST/NCoR fusion protein containing 
amino acids 2110-2453 of NCoR was examined for the ability to interact with 
in vitro translated and radioactively labeled PPARa, RARy and RXRa. PPARa 
interacted strongly with GST/NCoR, but not GST alone, in the absence of 
ligand (Fig. 4.28, lanes 2 and 10).  In contrast to our observations in yeast, 
PPARa also interacted with GST/NCoR in the presence of WY-14,643 (Fig. 
4.2B, lanes 2 and 3).  This interaction, however, was reduced 1.7-fold 
compared to that in the absence of ligand as determined by quantitative 
densitometric scanning (Fig. 4.28, lanes 2 and 3).  Similarly, RARy interacted 
with GST/NCoR and 9-cis RA reduced the interaction by 2.3-fold (Fig. 4.2B, 
lanes 5 and 6).  As observed in yeast, RXRa interacted weakly with 
GST/NCoR and 9-cis RA stimulated this interaction 3.4-fold (Fig. 4.2B, lanes 
8 and 9). A similar weak but ligand-enhanced interaction between RXR and 
the related corepressor, SMRT, has been observed by Chen and coworkers 116 
Fig. 4.2.  Interactions between NCoR and PPARa, RARy and RXRa. 
A, Interactions between NCoR and nuclear receptors in yeast.  LexA 
DBD/receptor fusions were coexpressed with a GAL4 AD/NCoR (amino acids 
2110-2453) fusion (GAD/NCoR) and examined for the ability to activate an 
integrated LexA-responsive lacZ reporter in the yeast strain L40.  Ligand­
dependent interactions were examined in the presence of 100 i.tM WY­
14,643, 1 p.M 9-cis RA or vehicle where indicated. At least three independent 
transformants were assayed for each experiment and the results shown 
represent the mean ± S.E.M for each determination. No reporter activity was 
detected when the GAD/NCoR fusion was coexpressed with either LexA 
DBD alone or LexA DBD fused to an unrelated protein (data not shown). 
Statistical significance at the 99% (p < 0.01) confidence level is indicated by 
** symbols for ligand versus vehicle treatment.  B, In vitro protein-protein 
interactions between NCoR and nuclear receptors. GST alone or GST fused 
to NCoR amino acids 2110-2453 (GST/NCoR) were bound to glutathione 
Sepharose and used as an affinity matrix to examine interactions with in vitro 
translated [35S]methionine-labeled PPARa, RARy and RXRa in the absence 
and presence of ligand (100 piNA WY-14,643 for PPARa or li.tM 9-cis RA for 
RARy and RXRa as indicated).  Input lanes (IN) represent 25% of receptor 
preparations used in binding reactions for the indicated samples. Note that 
the signals present in lanes 7-9 were obtained by increased exposure time 
relative to those in all other lanes.  All receptors preparations expressed in 
yeast or translated in vitro were truncated in the amino terminal (AAB) region 
(see "Materials and Methods"). Fig. 4.2. 
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(Chen and Evans, 1995).  In addition, Seol and collaborators observed an 
approximately 3-fold increased interaction between NCoR/RIP13 (see Fig. 
4.1. legend) and RXR in the presence of 9-cis RA (Seol, et al., 1995). 
To further probe the ligand-dependence of PPARa -NCoR interactions, 
several additional PPAR ligands were examined using the yeast two hybrid 
system as described above. Clofibrate, LY-171883 and ETYA, as well as the 
PPARy specific ligand, troglitazone, had no significant effects on PPARa-
NCoR interactions in yeast (Fig. 4.3A). The only ligand examined in yeast 
that efficiently promoted dissociation of PPARa and NCoR was WY-14,643 
and this effect was dose-dependent with an apparent IC50 of 134 nM (Fig. 
4.38). 
4.4.3.  NCoR and p300 require distinct PPARa amino acids for
interaction and NCoR ID II  is not necessary for PPARa-NCoR
interactions 
To determine which regions of PPARa are required for association 
with NCoR, we examined GST/NCoR interactions with several carboxyl- and 
amino-terminal PPARa truncation mutants (Fig. 4.4A). As shown above, the 
amino-terminally truncated receptor, PPARa, interacted strongly with both 
GST/NCoR and GST/p300 (Fig. 4.4.B, lanes 4-7). The former interaction was 
modestly inhibited by ligand while the latter interaction was strictly ligand­
dependent.  In contrast, PPARaA448 which lacks 21 carboxyl-terminal amino 
acids, efficiently interacted with GST/NCoR but ligand-dependent interaction 
between PPARaA448 and GST/p300 was abolished (Fig. 4.4B, lanes 11-14). 
The hinge/LBD region of PPARa, PPARa D/E, interacted with GST/NCoR and 
GST/p300 in a manner similar to that of PPARa although the WY- 14,643­
dependent PPARa D/E-GST/NCoR dissociation was more striking (Fig. 4.4B, 119 
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Fig. 4.3.  Influence of PPAR ligands on NCoR-PPARa interactions. 
A, Ligand dependent dissociation of NCoR and PPARa in yeast. PPARa 
interaction with NCoR was examined in the presence of 1  i.tM 9-cis RA, 100 
11M troglitazone, 1 mM clofibrate, 100 i.tM LY-171883, 100 liM ETYA, 10011M 
WY-14,643 or vehicle where indicated.  Statistical significance at the 99% (p 
< 0.01) confidence level is indicated by ** symbols for ligand versus vehicle 
treatment.  B, WY-14,643 dose-response curve for dissociation of NCoR-
PPARa in yeast.  PPARa interaction with NCoR was examined in the 
presence of increasing concentrations of WY-14,643 (1 nM, 10 nM, 100 nM, 
1 JIM, and 10 [tM) or vehicle. PPARa-NCoR interactions were examined as 
described in Fig. 4.2A. 120 
lanes 18-21).  In contrast, PPARa E which lacks residues contained within 
the hinge region of PPARa (amino acids 166-281), did not interact with either 
GST/NCoR or GST/p300 (Fig. 4.4B, lanes 25-28). These results demonstrate 
that both NCoR and p300 require the hinge region of PPARa for efficient 
interaction while only the latter requires the additional 21 carboxyl-terminal 
PPARa amino acids.  Therefore, the regions of PPARa required for 
interaction with NCoR and p300 are partially overlapping but largely distinct. 
The carboxyl-terminal PPARa truncation mutants, PPARaA425, 
PPARaA288 and PPARaA227, interacted efficiently with GST/NCoR (Fig. 
4.4C, lanes 3, 6 and 9). PPARaA,202, which lacks the entire LBD and 80% of 
the putative PPARa CoR box, also interacted with GST/NCoR (Fig. 4.4C, lane 
12). PPARa amino acids 166-201 within the hinge region are common to all 
receptor proteins observed to interact with GST/NCoR suggesting that these 
residues mediate PPARa interactions with NCoR. 
Similar in vitro protein-protein interaction studies with a GST/NCoR 
fusion protein lacking the entire ID II, GST/NCoR (MD II), demonstrate that the 
ID II region of NCoR is not required for interaction with PPARa (Fig. 4.5). As 
observed for interactions between PPARa and GST/NCoR (amino acids 
2110-2453, see Fig. 4.2B, lanes 2 and 3), WY-14,643 reduced but did not 
abolish the interaction between GST/NCoR (MD II) and PPARa (Fig. 4.5, 
lanes 4 and 5). 
4.4.4. PPARa ligands promote both PPARa-NCoR dissociation 
and PPARa-p300 association 
The yeast two hybrid system was used to compare the influence of 
several PPAR ligands on receptor interactions with the corepressor, NCoR 
(amino acids 2110-2453), and the coactivator, p300 (amino acids 39-221). 121 
Fig. 4.4.  Interactions between NCoR and truncation mutants of 
PPARa. A, Schematic representation of PPARa truncation mutants and 
summary of NCoR and p300 binding activity.  PPARa A/B, C, D and E 
domains are as defined in Issemann et al., (1990).  Stip led boxes (PPARa 
amino acids Lys196-A1a225) represent the putative CoR box conserved in TR 
and RAR (Horlein et al., 1995) Note that PPARa refers to an amino-terminally 
truncated receptor lacking the NB domain as oppossed to PPARa full-length 
(see Materials and Methods). B, In vitro protein-protein interactions between 
PPARa truncation mutants and both GST/NCoR (2110-2453) and GST/p300 
(39-221).  Assays were carried out as described in Fig. 4.2B and ligand 
concentrations were the same as those indicated in Fig. 4.3A.. C, In vitro 
protein-protein interactions between PPARa carboxyl-terminal truncation 
mutants and GST/NCoR (2110-2453). Assays were conducted as described 
above (Fig. 4.48). 
Fig. 4.5.  ID II of NCoR is not required for interaction with PPARa.
In vitro protein-protein interactions between PPARa and amino acids 
encompassing ID I, but not ID II, of NCoR (amino acids 2218-2381, see Fig. 
4.1).  Assays were carried out as described in Fig. 4.28 with GST or 
GST/NCoR (MD II). 
Fig. 4.6.  Influence of ligands on NCoR and p300 interactions with 
PPARa. A, Interactions between PPARa D/E and both NCoR (amino acids 
2110-2453) and p300 (amino acids 39-21) in yeast. Assays were conducted 
as described in Fig. 4.3A.  Statistical significance at the 95% (p < 0.05) and 
99% (p < 0.01) confidence levels are indicated by * and ** symbols, 
respectively, for ligand versus vehicle treatment. B, In vitro protein-protein 
interactions between PPARa D/E and both GST/NCoR (2110-2453) and 
GST/p300 (39-221). Assays were carried out as described in Fig. 4.28 and 
ligand concentrations were the same as those indicated in Fig. 4.3A. C, In 
vitro protein-protein interactions between PPARa and both GST/NCoR and 
GST/p300. Assays were carried out as described above (Fig. 4.5B). 122 
Fig. 4.4.
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PPARa D/E was used as the receptor component in  this series of 
experiments because we previously observed a readily detectable WY­
14,643-enhanced interaction in yeast between the D/E region of PPARa and 
p300 amino acids 39-221 (Dowell, et al., 1997a). As observed for yeast two 
hybrid analyses using PPARa (see Fig.  4.3.), WY-14,643, but not 
troglitazone, clofibrate, LY-171883 or ETYA, significantly repressed the 
interaction  between PPARa D/E and NCoR (Fig. 4.5A).  Similarly, 
troglitazone, clofibrate and LY-171883 had no significant influence on the 
strong ligand-independent PPARa D/E interaction with p300 while, in 
contrast, both ETYA and WY-14,643 modestly but significantly enhanced this 
interaction (Fig. 4.5A). 
To confirm the observed interactions in yeast, in vitro protein-protein 
interaction assays were conducted as described above. GST/NCoR (amino 
acids 2110-2453) and GST/p300 (amino acids 39-221) were examined for 
interaction with both PPARa D/E and PPARa in the absence and presence of 
several PPAR ligands. As demonstrated above (Fig. 4.4B, lanes 18 and 19), 
WY-14,643 inhibited the interaction between GST/NCoR and PPARa D/E 
approximately 2.5-fold as determined by quantitative densitometric scanning 
(Fig. 4.5B, lanes 8 and 13).  Clofibrate, LY-171883 and ETYA also weakly 
inhibited the interaction between GST/NCoR and PPARa D/E by 1.2-, 1.3-, 
and 1.5-fold, respectively, while troglitazone had no effect (Fig. 4.5B, lanes 9­
12).  Similar results were obtained upon examining interactions between 
GST/NCoR and PPARa (Fig. 4.5C, lanes 8-13).  In contrast, association 
between GST/p300 and both PPARa D/E and PPARa was observed only in 
the presence of ETYA or WY-14,643 (Fig. 4.5.B and C, lanes 18 and 19). 
Thus, ETYA and WY-14,643 promote p300-PPARa interactions both in yeast 
and in vitro suggesting that both ligands are permeable to the yeast cell. 126 
ETYA and WY-14,643 also promote NCoR-PPARa dissociation in vitro but, 
surprisingly, only WY-14,643 has a similar influence when examined in 
yeast. 
4.5.  Discussion 
We have demonstrated that PPARa interacts strongly with NCoR 
amino acids 2110-2453 and the PPARa ligand, WY-14,643, inhibits this 
interaction both in yeast and in vitro  .  The PPARa ligand, ETYA, also inhibits 
PPARa -NCoR interaction in vitro but, surprisingly, fails to influence this 
interaction in yeast. The lack of detectable influence by some ligands on 
PPARa interactions with NCoR in yeast may be the result of ligand 
impermeability to the yeast cell. However, the yeast strain used in our assay 
appears to be at least partially permeable to both ETYA and WY-14,643 as 
both ligands promote significant interactions between PPARa and the 
coactivator, p300. Although our yeast assays were conducted with saturating 
concentrations of ligand, we cannot be certain that such concentrations are 
reached inside the yeast cell.  Therefore, one explanation for our discrepant 
results regarding the influence of ETYA on NCoR-PPARa interactions in vitro 
versus in yeast is that the concentration of ETYA required to promote efficient 
dissociation of NCoR and PPARa is attained in vitro but not in yeast. This 
interpretation may suggest that different concentrations of ETYA are required 
to influence PPARa-NCoR and PPARa-p300 interactions.  Alternatively, 
enzymatic conversion of PPARa ligands by yeast metabolic pathways may 
explain our discrepant results regarding ETYA. For example, it is possible 
that in vitro, ETYA effectively influences PPARa interactions with both NCoR 
and p300, while in the yeast cell, ETYA is converted to a compound that 127 
promotes PPARa-p300 interactions yet has no influence on PPARa-NCoR 
interactions.  Lastly, it is also possible that ETYA may elicit production of an 
endogenous yeast compound that promotes PPARa-p300 interaction but not 
dissociation of PPARa and NCoR.  Furthermore, we cannot rule out the 
possibility that a combination of the events proposed above may be 
responsible for our observations. 
We hypothesized from our previous observations that PPARa exists in 
a liganded state in yeast that may not favor receptor-corepressor interactions 
due to putative endogenous ligands within the yeast cell (Dowell, et al., 
1997a).  The putative endogenous yeast ligand may not be present at 
sufficient concentrations to influence PPARa interaction with NCoR or simply 
may have no influence on this interaction perhaps in a manner similar to that 
of ETYA or potential metabolic derivatives thereof. These hypotheses may 
provide an explanation for the unexpected isolation of NCoR as a PPARa­
interacting protein  in  the yeast two hybrid screen described here. 
Nonetheless, our results clearly demonstrate that the PPARa ligand, WY­
14,643, promotes both PPARa-NCoR dissociation and PPARa-p300 
association in vitro and in yeast. 
Previously we demonstrated that the coactivators, p300 and SRC-1, 
require 21 carboxyl-terminal residues of the PPARa LBD for interaction with 
PPARa (Dowell, et al., 1997a). By analogy with other nuclear receptors, this 
region of PPARa is predicted to contain the putative ligand dependent-
transcriptional activation function (AF-2). We demonstrate here that the 
PPARa truncation mutant, PPARaA448, which is lacking the 21 carboxyl­
terminal amino acids that encompass the putative AF-2, interacts with NCoR 
but not p300. Therefore, the corepressor, NCoR, and the coactivators, p300 128 
and SRC-1, appear to utilize distinct regions of PPARa as protein-protein 
interaction surfaces. 
Deletion of the hinge region of PPARa (amino acids 166-281) 
abolished NCoR-PPARa interaction and amino acids 166-201 within the 
amino-terminal portion of the PPARa hinge were common to all receptor 
fragments that exhibited interaction with NCoR. These results suggest that 
35 residues, PPARa amino acids 166-201, mediate PPARa-NCoR 
interactions. PPARa sequence alignments with RAR and TR indicate that the 
putative PPARa CoR box lies between amino acids 196-225. However, of 
the 8 CoR box residues that are 100% conserved in RAR and TR (Horlein, et 
al., 1995), only 50% are conserved in the homologous region of PPARa (data 
not shown).  In addition, the PPARa mutant, PPARaA202 (amino acids 91­
201), which interacts efficiently with NCoR, is lacking 80% of the putative 
CoR box and contains only 1 of the 8 highly conserved CoR box residues. 
Therefore, our results suggest that PPARa likely contains a strong NCoR­
interaction surface distinct from that of the CoR box which mediates NCoR 
interactions with both TR and RAR (Horlein, et al., 1995). 
PPARy has been shown to interact with the corepressors, SMRT and 
NCoR, in solution but weakly if at all when bound to DNA in the context of a 
PPARy/RXR heterodimeric complex (Zamir, et al., 1997). Similarly, we were 
unable to demonstrate the formation of a DNA bound PPARa/RXRa/NCoR 
complex  (data  not  shown).  However, MAP kinase-dependent 
phosphorylation of PPARy has been demonstrated to promote both PPARy-
SMRT interaction and PPARy/SMRT-dependent transcriptional repression, 
although receptor-corepressor complex formation on DNA was not 
addressed (Lavinsky, et al., 1998).  These findings indicate that, in the 
appropriate context, PPARs may indeed  interact functionally with 129 
corepressors and inhibit expression of target genes.  In addition, allosteric 
effects from some DNA response elements to which PPARs bind may 
promote functional interactions between PPARs and corepressors. Such a 
mechanism has been demonstrated for the orphan receptor, Rev Erb, which 
interacts with NCoR and represses transcription when bound to a response 
element containing a direct repeat of the hexameric sequence, AGGTCA, 
separated by two bases (RevDR2). When bound to a single AGGTCA site 
(Rev monomer), however, Rev Erb does not interact with NCoR and 
accordingly does not repress transcription (Zamir, et al., 1997). Regardless 
of PPAR-corepressor complex formation on DNA, the possibility remains for 
cross-talk between PPARs and other nuclear receptors through common 
interactions with corepressors.  PPAR-corepressor interactions in solution 
may effectively titrate limiting amounts of corepressor thereby relieving 
transcriptional repression mediated by RAR, TR, Rev Erb or chicken 
ovalbumin upstream promoter-transcription factor I (COUP-TFI), all of which 
functionally interact with NCoR (Horlein, et al., 1995; Zamir, et al., 1997; 
Shibata, et al., 1997).  Nonetheless, further studies will be required to 
unequivocally establish the role of NCoR and other corepressors in PPAR-
mediated signaling.  The studies presented here provide additional 
information toward that goal. 
4.6.  Abbreviations 
The abbreviations used are: PPAR, peroxisome proliferator-activated 
receptor; RXR, retinoid X receptor; DR1, direct repeat separated by one 
nucleotide; ETYA, 5,8,11,14-eicosatetraynoic acid; RAR, retinoic acid 
receptor; TR, thyroid hormone receptor; NCoR, nuclear receptor corepressor; 
SMRT, silencing mediator of retinoid and thyroid hormone receptors; HAT, 130 
histone deacetyltransferase; CBP, CREB binding protein; SRC-1, steroid 
receptor coactivator-1; p/CIP, p300/CBP-interacting protein; mPPARa, mouse 
PPARa; ID, interaction domain; 9-cis-RA, 9-cis-retinoic acid; RIP13, RXR-
interacting protein 13; GAD, GAL4 activation domain; COUP-TFI, chicken 
ovalbumin upstream promoter transcription factor I. 
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Discussion
 
Peroxisome proliferator-activated receptors (PPARs) are thought to 
mediate the effects of several pharmacological agents and PPAR ligands that 
are used to treat a variety of human maladies.  The synthetic fibrates, 
gemfibrozil and clofibric acid, effectively lower serum triglyceride levels by 
promoting expression of enzymes involved in lipid catabolism through a 
PPARa-dependent mechanism (Witzum, 1995).  The thiazolidinediones 
(TZDs), troglitazone and pioglitazone, increase insulin sensitivity in skeletal 
muscle and adipose tissue of non-insulin dependent diabetic patients 
through a poorly understood, but PPARy-dependent mechanism (Nolan, et 
al.,  1994).  The non-steroidal anti-inflammatory drugs, ibubrofen and 
indomethacin, mediate their effects, at least partially, through PPARy­
dependent antagonism of inflammatory cytokine production (Jiang, et al., 
1998; Ricote, et al., 1998).  Thus, pharmacological manipulation of PPAR 
signaling pathways has proven useful in the treatment of human disease. 
A more thorough understanding of the molecular mechanisms of 
PPAR signaling may aid in improving therapeutic strategies that target 
PPARs as the molecular site of action.  In addition, the risk of potentially 
harmful side effects may be decreased if specific components of these 
signaling pathways can be individually manipulated. Indeed, recent findings 
suggest that ligand-activated PPARy may promote foam cell formation, one of 
the earliest steps in artherogenesis, thus raising concerns about the use of 136 
TZDs for the treatment of non-insulin dependent diabetes (Tontonoz, et al. 
1998; Spiegelman, 1998).  In addition, synthetic fibrates used to treat 
hypertriglyceridemias are potent hepatocarcinogens in rodents (Lake, 1995). 
The aim of the studies described here was to contribute additional 
knowledge as to the molecular mechanisms of PPAR signaling toward the 
larger goal of improving, or developing novel, PPAR-dependent therapeutic 
strategies. 
The synthetic  fibrates, WY-14,643 and clofibric  acid, were 
demonstrated to directly induce PPARa conformational changes as 
evidenced by a differential protease sensitivity assay.  Conformational 
changes were induced in a dose-dependent manner which paralleled that of 
WY-14,643 to induce transcriptional activation.  Direct interaction of ligands 
with, and the resulting conformational alterations in, PPARa may facilitate 
interaction of the receptor with transcriptional intermediary factors and thus 
may underlie the molecular basis of ligand-dependent transcriptional 
activation mediated by PPARa. 
The yeast two hybrid screen was utilized to identify downstream 
components of the PPARa signaling pathway.  Using this technique, the 
coactivator proteins, p300 and steroid receptor coactivator-1 (SRC-1), were 
identified as PPARa-interacting proteins and WY-14,643 promoted these 
interactions. p300 also enhanced the transcriptional activation properties of 
PPARa and, therefore, can be considered a bona fide coactivator for this 
nuclear receptor.  Interestingly, the retinoid receptors, retinoic acid receptor 
(RAR) and retinoid X receptor (RXR), also interacted with p300 in a ligand­
enhanced manner, however, different regions of p300 were required for 
interaction with RAR and RXR compared to that of PPARa. These results may 
be relevant to the functioning of receptor-coactivator complexes in vivo 137 
where several receptors may be in competition for limiting amounts of 
coactivator protein. 
Nuclear receptor corepressor (NCoR) was also isolated as a PPARa­
interacting protein from a yeast two hybrid screen.  In contrast to the WY­
14,643 enhanced PPARa-coactivator interactions, WY-14,643 inhibited 
receptor-NCoR interactions.  Protein-protein interaction mapping studies 
suggest that the NCoR-interacting region of PPARa is distinct from that of 
homologous regions from other nuclear receptors which interact with NCoR. 
Lastly, NCoR and the coactivators, p300 and SRC-1, were demonstrated to 
require distinct receptor regions for efficient interaction with PPARa. 
In summary, WY-14,643 was demonstrated to:  1) induce PPARa 
conformational changes, 2) promote PPARa-coactivator (p300 and SRC-1) 
interactions, and 3) inhibit PPARa-NCoR interactions. We hypothesize that 
such molecular events are critical for ligand-dependent transcriptional 
activation by PPARa and most likely all PPAR subtypes.  These results 
contribute additional knowledge as to the molecular mechanisms of PPAR-
dependent signaling and may act as a starting part for the improvement 
and/or development of therapeutic strategies aimed at manipulating this 
signaling pathway 
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